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A B S T R A C T
Background
Neurocysticercosis is a parasitic infection of the central nervous system by the larval stage of the pork tapeworm and is a common cause
of seizures and epilepsy in endemic areas. Anthelmintics (albendazole or praziquantel) may be given alongside supportive treatment
(antiepileptics/analgesia) with the aim of killing these larvae (cysticerci), with or without corticosteroid treatment. However, there are
potential adverse eIects of these drugs, and the cysticerci may eventually die without directed anthelminthic treatment.
Objectives
To assess the eIects of anthelmintics on people with neurocysticercosis.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, Embase, LILACS, the WHO ICTRP, and ClinicalTrials.gov, up to 21 October 2020.
Selection criteria
Randomized controlled trials comparing anthelmintics and supportive treatment (+/- corticosteroids) with supportive treatment alone (+/-
corticosteroids) for people with neurocysticercosis.
Data collection and analysis
Two review authors independently screened the title and abstract of all articles identified by the search. We obtained full-text articles to
confirm the eligibility of all studies that passed screening. One review author extracted data, which a second review author checked. Two
review authors assessed the risk of bias of each trial and performed GRADE assessments. In cases of disagreement at consensus discussion
stage between review authors, we consulted a third review author. We calculated risk ratios (RR) for dichotomous variables, with 95%
confidence intervals (CIs) for pooled data from studies with similar interventions and outcomes.
Main results
We included 16 studies in the review. Only two studies investigated praziquantel and did not report data in a format that could contribute
to meta-analysis. Most results in this review are therefore applicable to albendazole versus placebo or no anthelmintic.
The aggregate analysis across all participants with neurocysticercosis did not demonstrate a diIerence between groups in seizure
recurrence, but heterogeneity was marked (RR 0.94, 95% CI 0.78 to 1.14; 10 trials, 1054 participants; I2 = 67%; low-certainty evidence).
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When stratified by participants with a single cyst or multiple cysts, pooled analysis suggests that albendazole probably improves seizure
recurrence for participants with a single cyst (RR 0.61, 95% CI 0.4 to 0.91; 5 trials, 396 participants; moderate-certainty evidence). All studies
contributing to this analysis recruited participants with non-viable, intraparenchymal cysts only, and most participants were children. We
are uncertain whether or not albendazole reduces seizure recurrence in participants with multiple cysts, as the certainty of the evidence is
very low, although the direction of eIect is towards albendazole causing harm (RR 2.05, 95% CI 1.28 to 3.31; 2 trials, 321 participants; very
low-certainty evidence). This analysis included a large study containing a highly heterogeneous population that received an assessment
of unclear risk for multiple 'Risk of bias' domains.
Regarding radiological outcomes, albendazole probably slightly improves the complete radiological clearance of lesions (RR 1.22, 95% CI
1.07 to 1.39; 13 trials, 1324 participants; moderate-certainty evidence) and the evolution of cysts (RR 1.27, 95% CI 1.10 to 1.47; 6 trials, 434
participants; moderate-certainty evidence).
More adverse events appeared to be observed in participants treated with either albendazole or praziquantel compared to those receiving
placebo or no anthelmintic. The most commonly reported side eIects were headache, abdominal pain, and nausea/vomiting.
Authors' conclusions
For participants with a single cyst, there was less seizure recurrence in the albendazole group compared to the placebo/no anthelmintic
group. The studies contributing to this evidence only recruited participants with a non-viable intraparenchymal cyst. We are uncertain
whether albendazole reduces seizure recurrence for participants with multiple cysts. We also found that albendazole probably increases
radiological clearance and evolution of lesions. There were very few studies reporting praziquantel outcomes, and these findings apply
to albendazole only.
P L A I N   L A N G U A G E   S U M M A R Y
Anthelmintics for people with neurocysticercosis
What is the aim of this review?
The aim of this review was to explore whether treatment with anthelmintics (drugs that kill worms) can benefit people with
neurocysticercosis (an infection of the brain caused by the pork tapeworm). The primary outcome of the review was the impact of treatment
on seizures (epilepsy). We collected and analysed all relevant studies (trials) to answer this question and found 16 studies. The most
commonly reported outcomes were those relating to seizures and also the number and appearance of lesions caused by viable or degrading
cysts (dormant worms) on brain imaging.
Key messages
We found that the anthelmintic albendazole probably reduces the recurrence of seizures in people with neurocysticercosis with a single cyst
(moderate-certainty evidence). We are uncertain whether albendazole reduces seizure recurrence for people with neurocysticercosis with
more than one cyst (very low-certainty evidence). We found little information regarding another anthelmintic drug, praziquantel; therefore
these results are applicable to albendazole only. Albendazole treatment also probably increases the clearance and evolution of cysts in
people with neurocysticercosis (moderate-certainty evidence). Evolution of a cyst is progression to a later cyst stage, which is thought to
be an improvement towards clearance.
What was studied in the review?
Neurocysticercosis is an infection of the brain with the pork tapeworm Taenia solium, which is caused by eating food or drinking water
contaminated with the eggs of the worm. The eggs can travel from the gut to the brain, forming cysts in the brain that can cause various
symptoms, the most common of which is seizures/epilepsy. Neurocysticercosis is found mainly in areas where people keep pigs and have
poor sanitation facilities, and is a common cause of seizures in areas where it is prevalent.
People with neurocysticercosis may have single or multiple cysts, and their symptoms depend on the position and numbers of these
cysts within the brain. Each cyst goes through the natural process of being alive and dormant (viable), degrading (non-viable), and then it
resolves or calcifies. This process can take many years. The number, type, and position of the cysts can be seen on brain imaging (lesions).
Two anthelmintics (drugs to treat worm infections), albendazole and praziquantel, are oOen used to treat neurocysticercosis. However, it
is uncertain whether they reduce or stop seizures and other symptoms, or make them worse. In theory, the body's immune response to
cysts dying as a result of treatment could cause more swelling and damage to the brain.
What are the main results of the review?
We included 16 studies in the review. These studies compared treatment with an anthelmintic versus placebo (a mock tablet/pill
resembling the anthelmintic) or no anthelmintic treatment in adults or children with neurocysticercosis diagnosed by brain imaging.
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For people with a single cyst, treatment with albendazole probably reduces seizure recurrence (moderate-certainty evidence). Notably,
all studies that contributed to this analysis only included people with non-viable cysts. For people with multiple cysts, the evidence was
of very low certainty, therefore we are uncertain whether or not albendazole reduces seizure recurrence for this group of patients. The
studies contributing to this finding included participants with cysts that were both viable and non-viable. We found very little information
regarding praziquantel, therefore these results are apply to albendazole only.
Treatment with albendazole probably increases complete clearance of lesions on brain imaging as well as the evolution of cysts (from
viable to non-viable to resolved or calcified) (moderate-certainty evidence). The studies contributing to this evidence included people with
single and multiple cysts, both viable and non-viable.
More side eIects were reported by participants treated with either albendazole or praziquantel compared to those receiving placebo or
no anthelmintic. The most commonly reported side eIects were headache, abdominal pain, and nausea/vomiting.
How up-to-date is this review?
We searched for studies that had been published up to 21 October 2020.
Anthelmintics for people with neurocysticercosis (Review)




































































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Albendazole compared with placebo or no anthelmintics for people with neurocysticercosis
Albendazole compared with placebo or no anthelmintics for people with neurocysticercosis
Population: people with neurocysticercosis
Settings: any healthcare setting
Intervention: albendazole
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Albendazole probably slightly improves the
evolution of cysts overall (all participants).
*The assumed risk is from the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval, RCT: randomized controlled trial, RR: risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
1Downgraded by one level for risk of bias: two studies have 'Risk of bias' domains assessed as high risk (Kalra 2003; Khurana 2012), and Das 2007 is at unclear risk of bias for
random sequence generation, allocation concealment, and blinding. Given the findings of Das 2007 and the number of participants, risk of bias would likely seriously alter the
results of this outcome.
2Downgraded by one level for inconsistency: substantial heterogeneity and clear heterogeneity in trial design for recruitment.
3Not downgraded for indirectness (all studies include clinical criteria to ensure new-onset seizures in the context of radiological +/- serological neurocysticercosis diagnosis),
imprecision (CI does not include RR values that would be considered appreciable benefit or harm), or publication bias.
4Downgraded by one level for imprecision: fewer than 300 events, and CI upper limit includes values that would be considered of little eIect.
5Not downgraded for risk of bias (most data are from studies with low risk of bias, and any risk of bias identified is unlikely to alter the results of this outcome), inconsistency (low
heterogeneity, and all studies recruited participants with non-viable intraparenchymal cysts only), indirectness (all studies include clinical criteria to ensure new-onset seizures
in the context of radiological +/- serological neurocysticercosis diagnosis), or publication bias.
6Downgraded by one level for risk of bias: Das 2007 is at unclear risk of bias for random sequence generation, allocation concealment, and blinding. Given the findings of Das
2007 and the number of participants, risk of bias would likely seriously alter the results of this outcome.
7Downgraded by one level for inconsistency: substantial heterogeneity and clear heterogeneity between participants.
8Downgraded by one level for indirectness: participants receiving albendazole in Das 2007 also received corticosteroids, whereas participants that did not receive albendazole
did not. Given that Das 2007 is the largest trial contributing to this outcome, the pooled results are less directly relevant to this review.
9Not downgraded for imprecision (CI lower limit does not include RR values that would be considered of little or no harm, and RR increase lower limit is greater than 25%) or
publication bias.
10Downgraded by one level for inconsistency: substantial heterogeneity.
11Not downgraded for risk of bias (most data are from studies with low risk of bias, and the results are unchanged if studies assessed as having a high risk of bias for any 'Risk of
bias' domain, Kalra 2003; Khurana 2012; Singhi 2000; Sotelo 1988, are excluded), indirectness (all studies include clinical criteria to ensure new-onset seizures in the context of
radiological +/- serological neurocysticercosis diagnosis), imprecision (over 300 events and large number of participants), or publication bias.
12Downgraded by one level for imprecision: fewer than 300 events, and CI lower limit includes values that would be considered of little eIect (RR increase < 25%).
13Not downgraded for risk of bias (most data are from studies with low risk of bias, and any risk of bias identified is unlikely to alter the results of this outcome), inconsistency
(very low heterogeneity, and most studies recruited participants with non-viable intraparenchymal cysts only), indirectness (all studies include clinical criteria to ensure new-
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B A C K G R O U N D
Description of the condition
Neurocysticercosis is an infection of the central nervous system
(CNS) by the cystic larval stage (cysticercus) of the pork tapeworm
Taenia solium. The natural life cycle of T solium is for a human
host infected with the adult intestinal worm to shed eggs (ova),
which can survive for several months before ingestion, or egg-filled
motile worm segments (gravid proglottids) into the environment.
These are subsequently ingested by pigs through contamination
of their diet. The ova hatch within the porcine gastrointestinal
tract to become oncospheres, invade the mucosa to gain access
to the bloodstream, migrate to various tissues and encyst to
become cysticerci. When a human ingests encysted pork, the
cysticerci attach to the intestinal mucosa and mature into adult
tapeworms, completing the life cycle. Human neurocysticercosis is
an aberration of this life cycle and occurs when a human (rather
than a pig) ingests the ova of T solium. Cysticerci (cysts) form
within various human tissues (cysticercosis), much the same as
within the porcine host. This review is confined to the treatment
of neurocysticercosis, where cysticerci form within the CNS of a
human host.
Neurocysticercosis is found where people live in close contact with
pigs and where sanitation is poor, allowing for a natural life cycle
of T solium to establish. Cases cluster around individuals with
taeniasis secondary to T solium, suggesting a larger proportion
of human-to-human infections via faecal-oral transmission rather
than through environmental contamination (Lescano 2009). It is
common in much of South and Central America, China, the Indian
subcontinent, South-East Asia, and sub-Saharan Africa, and is
estimated cause to epilepsy (presenting as recurrent seizures) in
over 1% of the population in endemic settings (Coyle 2012; Savioli
2010). It is the leading cause of adult-onset epilepsy worldwide,
and is estimated to cause at least 50,000 deaths each year (Roman
2000). Neurocysticercosis is therefore a significant public health
problem, burdening not only healthcare systems with significant
costs, but also households and communities with lost productivity
through morbidity and mortality.
The cysts in neurocysticercosis naturally evolve over a period
of years, beginning with viable encysted larvae and ending with
the death of the parasite and either resorption (clearance) or
calcification of the cyst. Individuals may have one or more
cysticerci in the brain, and multiple cysts can represent one
point of contact or cumulative exposure. Depending on the
site of the cysts, neurocysticercosis can be intraparenchymal
(most frequently between white/grey matter boundary) or
extraparenchymal. Extraparenchymal disease can be further
subdivided: intraventricular (most frequently in the fourth
ventricle); racemose (a severe variant with large, multi-lobar
cysts in the subarachnoid space, oOen complicated by basal
cisterns or Sylvian fissure involvement); and spinal (an extracranial
manifestation of subarachnoid disease). Symptoms may or may not
occur, depending on the number, location, and stage of the cysts,
as well as the extent of the infected individual's immune response.
Although there is a wide spectrum of clinical manifestations of
neurocysticercosis, seizures are the most common presentation,
followed by headaches, focal neurological deficit, and signs
of raised intracranial pressure (Carabin 2011). Intraparenchymal
neurocysticercosis has a much more favourable prognosis than
extraparenchymal; intraparenchymal disease has a very low
mortality, usually presenting as seizures that respond well to
antiepileptic medication, whereas extraparenchymal disease has
a significant rate of mortality in endemic areas without the
availability of optimal surgical treatment (Degiorgio 2002).
Cysts within the CNS can be visualized using computed tomography
(CT) or magnetic resonance imaging (MRI); these radiological
findings underpin the diagnostic criteria required for definitive
diagnosis (Del Brutto 2017). Over the course of an infection,
radiological images of a lesion change from 'non-enhancing' (aOer
intravenous injection of a radiographic contrast), indicating a viable
cyst with little or no associated inflammation, to 'ring-enhancing',
indicating a degenerating (non-viable) cyst with surrounding
infiltration secondary to the host's immune response. These cysts
can either progress to resolution or calcification (Degiorgio 2004).
Symptoms can develop at any point during the course of an
infection and can be associated not only with the structural
and functional abnormality caused by the cyst and surrounding
inflammation, but also the calcification that remains aOer a cyst has
been eliminated (Leite 2000). Infection burden varies widely, and is
cumulative with repeat exposure (Garcia 2002).
Description of the intervention
Treatment options depend on the number, size, and location of
cysts and the individual's symptoms. Initial symptomatic treatment
includes antiepileptic medication for seizures and analgesia for
headache. Some extraparenchymal cysts are treated with surgery,
either to remove the cyst or to relieve intracranial pressure. Where
significant inflammation of the brain is present (usually associated
with cyst degeneration), corticosteroids may be administered.
Two anthelmintic medications are used for the management
of neurocysticercosis: praziquantel and albendazole, available
since 1979 and 1987, respectively. Anthelmintics were previously
considered only for people with viable cysts, with the aim of killing
the live parasites. More recently, however, guidelines authored
by expert panels present a stronger recommendation for using
anthelmintics for both viable and non-viable cysts, unless diIuse
cerebral oedema or hydrocephalus are present (White 2018). If
anthelmintics are used, corticosteroids are oOen prescribed to
prevent inflammation of the brain caused by the host immune
response to the co-ordinated death of multiple parasites.
Why it is important to do this review
The original version of this Cochrane Review found no evidence that
the potential benefits of treatment outweigh the potential harms
(Salinas 1999). An update in 2010 found that albendazole treatment
at a standard dose in children with small numbers of non-viable
intraparenchymal cysts may reduce the risk of recurrence between
six to 18 months. In studies recruiting adults with viable cysts,
the results suggested that albendazole may increase radiological
clearance (Abba 2010).
This latest review update was undertaken as a substantive update
of the 2010 Cochrane Review (Abba 2010) to take studies published
since 2010 into account. Compared to previous versions (Abba
2010; Salinas 1999), this review focused more on the core question
of whether anthelmintics are of benefit or harm in the management
of neurocysticercosis compared to no anthelmintic, as there was
insuIicient evidence in previous versions of the review to answer
this question. Comparisons between anthelmintic regimens were
Anthelmintics for people with neurocysticercosis (Review)
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not made, and the inclusion criteria were updated to reflect this
change.
We considered stratification of participants by age (children,
defined as under 16 years of age, and adults), by whether
participants had viable or non-viable cysts (given the natural
history and assumptions about when anthelmintics may or
may not be eIective), by the intraparenchymal/extraparenchymal
anatomical site of the cysts, and by number of cysts (single or
multiple) for each comparison, presenting the stratified data if the
result added to the overall outcome finding.
O B J E C T I V E S
To assess the eIects of anthelmintics on people with
neurocysticercosis.
M E T H O D S




People with symptomatic or asymptomatic neurocysticercosis
defined by viable or non-viable cysts in the brain, identified as 'non-




• Anthelmintics plus supportive treatment (antiepileptics/
analgesia)
• Anthelmintics plus corticosteroids plus supportive treatment
Control
• Supportive treatment only
• Corticosteroids plus supportive treatment
We included trials irrespective of the type of anthelmintic used, or
the dosage and duration of treatment.
Types of outcome measures
Primary outcomes
Seizure status at follow-up
• Seizure recurrence
• Seizure recurrence aOer withdrawal of antiepileptics
• Time to seizure remission*
• Frequency of seizures (< 1/1 to 3/4+ per month)
*Defined as being free from seizures for the previous 12 months or
for the duration of follow-up (if follow-up was less than 12 months).
Secondary outcomes
Secondary health status indicators at follow-up
• Death (any cause)
• Hospital admission (any cause)
• Headache
• Signs of focal neurological deficit (e.g. paralysis, visual
disturbance)
• Surgical intervention
• Resolution of symptoms
• Resumption of normal activities
Radiological findings at follow-up
• Complete radiological clearance of lesions
• Reduction of number of lesions
• Evolution of cysts (viable to non-viable/resolved/calcified or
non-viable to resolved/calcified)
• Radiological resolution/development of oedema
• Radiological resolution/development of raised intracranial
pressure
Adverse events associated with treatment (side e@ects) at follow-up
• Frequency and nature of adverse events
• Adverse event requiring withdrawal of anthelmintics
Search methods for identification of studies
We aimed to identify all relevant studies regardless of language
or publication status (published or unpublished, in press, or in
progress).
Electronic searches
We searched the following databases using the search terms
and strategy described in Appendix 1 up to 21 October
2020: Cochrane Infectious Diseases Group Specialized Register;
the Cochrane Central Register of Controlled Trials (CENTRAL),
published in the Cochrane Library, Issue 10 of 12, October
2020; MEDLINE (PubMed, from 1966); Embase (Ovid, from
1947); and LILACS (Latin American and Caribbean Health
Science Information database) (BIREME, from 1982). We also
searched the World Health Organization International Clinical
Trials Registry Platform (WHO ICTRP; www.who.int/clinical-trials-
registry-platform) and US National Institutes of Health Ongoing
Trials Register ClinicalTrials.gov (clinicaltrials.gov/ct2/home) for
trials in progress, using “neurocysticercosis ” and “Taenia solium”
as search terms.
Searching other resources
We checked the reference lists of all studies, articles, and reviews
identified by the above search terms for additional eligible studies.
Data collection and analysis
Selection of studies
Two review authors (EJMM and either KA or LNR) independently
screened all citation titles and abstracts using a selection criteria
eligibility form to identify all relevant studies. Where it was unclear
if a study met our eligibility criteria or it appeared to be eligible,
we obtained the full-text article for assessment. Any diIerences of
opinion were resolved by consensus discussion or by consulting
the third review author if necessary. Studies that did not meet the
criteria at any point in assessment were excluded.
Anthelmintics for people with neurocysticercosis (Review)
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Data extraction and management
One review author (EJMM) extracted data using a tailored data
extraction form in which data were stratified by age (child/adult),
cyst viability (viable/non-viable/mixed), and anatomical position
(intraparenchymal/extraparenchymal/mixed) for each outcome.
The form also captured the studies' intervention/control regimens
in detail, the inclusion/exclusion criteria of each study, and the
follow-up duration of each result extracted. A second review
author (KA) checked the extracted data, with any disagreements
resolved by discussion. The extracted data were entered into
Review Manager 5 (Review Manager 2020).
Assessment of risk of bias in included studies
Two review authors (EJMM and either KA or LNR) independently
assessed the risk of bias of the included studies using a pro forma
based on Cochrane's tool for assessing risk of bias, described in
the Cochrane Handbook for Systematic Reviews of Interventions
(Boutron 2021). We categorized the generation of the allocation
sequence and allocation concealment as adequate, unclear, or
inadequate (Jüni 2001). We assessed whether the participants,
care providers, and investigators were blinded to the drug regimen
received by participants (intervention or control) as well as
staI reporting imaging. For all outcomes, we assessed whether
incomplete outcome data had been adequately addressed; if less
than 85% of participants were included, adequate steps must have
been documented to demonstrate that this did not lead to biased
results to not be considered at unclear or high risk of bias. We also
examined the articles for any evidence of selective reporting of
outcomes or any other issues that could have biased the results. In
cases of disagreement aOer consensus discussions, the third review
author was consulted.
Measures of treatment e@ect
We used risk ratio (RR) as the measure of treatment eIect for
analysis.
Unit of analysis issues
We extracted data at the participant-level for all outcomes, rather
than at the lesion-level. If studies reported radiological outcomes
at lesion-level only, they were included in the results narrative but
not the meta-analysis.
Dealing with missing data
If loss to follow-up was less than 15%, we considered studies to be
at low risk of bias for incomplete data. We considered studies with
loss to follow-up of 15% to 20% to be at low, unclear, or high risk
of bias, depending on the circumstances and reporting of reasons
for loss to follow-up. We considered studies with loss to follow-up
of over 20% to be at high risk of bias, unless the loss was clearly
accounted for in the articles, with no evidence of bias. Where data
were presented in a manner that did not allow for stratification by
our variables of interest, we approached the corresponding study
authors for additional details. If unpublished data were provided,
we have stated this in the Included studies section of the References
section.
Assessment of heterogeneity
We assessed the heterogeneity for each outcome by considering
the I2 statistic. We considered values of > 60% as indicative of
substantial heterogeneity, 40% to 60% moderate heterogeneity,
and < 40% low heterogeneity. We explored heterogeneity further in
subgroup analysis.
Assessment of reporting biases
We assessed the probability of publication bias by examining a
funnel plot for asymmetry for the primary outcome with the largest
number of contributing studies, as well as the overall outcome with
the largest number of contributing studies, given the diIerent bias
implications in clinical seizure and radiological reporting.
Data synthesis
We analysed extracted data using Review Manager 5 (Review
Manager 2020). We calculated RR for dichotomous data and
mean diIerence (MD) for continuous data. We measured precision
using 95% confidence intervals (CIs). Where more than one study
included similar participants and interventions, without significant
clinical or methodological diversity, we undertook a meta-analysis
using a fixed-eIect model. Highly skewed data (where the standard
deviation was greater than the mean) were presented in the text,
as were any data from trials that could not be extracted due to the
reporting format.
In studies with more than one follow-up point, the latest follow-
up point was used for analysis unless the follow-up points (within
the same study) diIered by more than 12 months, in which case
the most similar follow-up point (compared to the follow-up of the
other contributing studies) was included in the analysis. The same
participant was not included at two points in time for any individual
analysis.
Subgroup analysis and investigation of heterogeneity
We investigated potential sources of heterogeneity for each
outcome by comparing the I2 statistic between subgroups
and the primary (pooled) analysis. We performed subgroup
analyses by age (child/adult), type of lesion (viable/non-viable/
mixed cysts), the anatomical position of cysts (intraparenchymal/
extraparenchymal/mixed), number of cysts (single/multiple),
and variations in intervention regimen (e.g. corticosteroids/no
corticosteroids), where reported, for all outcomes and presented
the results where they changed the interpretation of the data.
Studies in which the data could not be stratified were not included
in subgroup analysis.
Sensitivity analysis
Where suIicient trial data were available, we undertook sensitivity
analyses by excluding studies without adequate reported
allocation concealment. We also performed sensitivity analysis to
address peculiarities of studies under investigation as they arose
during the review process. These analyses were performed for all
outcomes and were reported where the results could potentially
change the interpretation of the data.
Summary of findings and assessment of the certainty of the
evidence
We chose which outcomes to present in the 'Summary of findings'
table based on two factors: the clinical significance of the
outcome, and the frequency at which an outcome is measured/
considered by clinicians in neurocysticercosis diagnosis and follow-
up. These were thought to be the resolution of seizures, given that
epilepsy is the most common presentation of neurocysticercosis,
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and radiological resolution/improvement of lesions (complete
radiological clearance of lesions and evolution of cysts). We
decided which outcomes to include also in the context of the
results of this review in order to include any unexpected findings of
importance.
We used the GRADE approach to formally assess the certainty
of the evidence for all outcomes, based on an assessment of
the risk of bias, inconsistency, indirectness, imprecision, and
publication bias of the collective evidence contributing to each
outcome (Ryan 2016; Schünemann 2021). Two review authors
(EJMM and KA) independently conducted this assessment, with any
disagreements resolved by discussion. The results of the GRADE
assessment for each of the outcomes included in our Summary of
findings 1 are discussed in the table's footnotes.
R E S U L T S
Description of studies
Results of the search
Our database search identified 628 articles that met our search
terms. AOer title/abstract screening,  we assessed 39 full-text
articles. We excluded 17  articles aOer full-text assessment:  six
because they did not report trials (commentaries, case reports,
and reviews). The remaining 11 excluded articles and the reasons
for their exclusion are presented in the Characteristics of excluded
studies. Figure 1 shows the screening and assessment flow of
articles identified by the search.
 
Figure 1.   Study flow diagram.
 
Of the 22 articles that met our inclusion criteria (reporting data
from 14 studies), we were unable to access one (a conference
abstract). We confirmed with the corresponding study author that
this article reported data that were duplicated by a journal article
also identified through the search.
Four additional articles, reporting data from two additional studies,
were identified through searching of reference lists of included
studies and published reviews identified by the search. We included
these in the review, contributing to a total of 25 accessible articles
reporting data from 16 studies.
Our search identified no relevant ongoing trials recruiting or yet to
recruit.
Included studies
Sixteen studies matched our inclusion criteria and are included
in this review (Figure 1, Characteristics of included studies). We
extracted data from 25 articles that reported the outcomes of these
studies. A trial ID was established for each study for reference
throughout this review using the first author's surname and year of
publication on the primary reference article.
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We have provided a  description of the included randomized
controlled trials  in Table 1. Three of these trials are new since
the last update of this review (Chaurasia 2010; Foyaca-Sibat 2001;
Khurana 2012), whilst the remaining 13 studies contributed to the
previous version of this review (Abba 2010).
Geographical location and time period
The included studies were mostly conducted in India (11 trials:
Baranwal 1998; Chaurasia 2010; Das 2007; de Souza 2009; Gogia
2003; Kalra 2003; Khurana 2012; Padma 1994; Padma 1995; Singhi
2000; Singhi 2004), or the Americas (four trials: two in Ecuador
(Alarcon 2001; Carpio 2008), one in Mexico (Sotelo 1988), and one
in Peru (Garcia 2004)). One study was conducted in South Africa
(Foyaca-Sibat 2001). Recruitment for most included studies was
conducted in the 1990s and 2000s, with only two studies including
recruitment in the late 1980s (Alarcon 2001; Sotelo 1988), and one
study recruiting participants in the early 2010s (Khurana 2012).
Participants
All participants were enrolled into the included studies on the basis
of CT or MRI radiological diagnosis of neurocysticercosis. In studies
reporting seizure outcomes, seizures prior to enrolment were also
an essential inclusion criteria. Two studies included serological
confirmation in addition to radiological findings (Das 2007; Garcia
2004).
The included studies diIered in their population inclusion/
exclusion criteria based on age, cyst viability, position of cysts
(intraparenchymal/extraparenchymal), and number of cysts. These
are detailed in the Characteristics of included studies tables and
summarized in Table 1. Participant age, cyst viability, and cyst
position required for recruitment are also demonstrated in Figure
2. Seven studies recruited participants with single cysts only
(Baranwal 1998; Chaurasia 2010; de Souza 2009; Khurana 2012;
Padma 1994; Singhi 2000; Singhi 2004). Das 2007 and Padma 1995
recruited participants with more than one cyst only. Participants
were recruited in three studies with 1 or more cysts (Carpio 2008;
Gogia 2003; Sotelo 1988); one study with 1 to 2 cysts (Kalra 2003);
one study with 1 to 6 cysts (Alarcon 2001); and one study with 1 to
20 cysts (Garcia 2004). Foyaca-Sibat 2001 did not state how many
cysts were required for recruitment.
 
Figure 2.   Venn diagram of study characteristics according to age of participants, viability of cysts, position of cysts,
and number of cysts. Children are defined as being < 16 years of age.
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Interventions
All but one study compared albendazole administration versus
placebo or no anthelmintic (Foyaca-Sibat 2001). Two studies
compared praziquantel administration versus placebo or no
anthelmintic (Foyaca-Sibat 2001; Sotelo 1988). The anthelmintic
dosing regimen and concurrent steroid and/or antiepileptic
therapy for each study varied greatly and is summarized in Table
2. Albendazole regimens varied from 3 to 28 days. Praziquantel
regimens varied from 1 to 14 days.
Corticosteroids were administered to all participants in three
studies (Baranwal 1998; Carpio 2008; Gogia 2003), and to
participants receiving the intervention only in five studies (Das
2007; Foyaca-Sibat 2001; Garcia 2004; Kalra 2003; Singhi 2004).
In one study, participants in both the intervention and control
arm received corticosteroids only if adverse events occurred that
indicated their use (Sotelo 1988). Steroids were not administered in
four studies (Alarcon 2001; Chaurasia 2010; de Souza 2009; Khurana
2012). In one study, it was unclear whether participants receiving
the intervention only received corticosteroids (Singhi 2000). Steroid
administration was not stated in two studies (Padma 1994; Padma
1995). Corticosteroid regimens varied from 3 to 21 days (Table 2).
Antiepileptic medications were administered to all participants in
10 studies (Chaurasia 2010; Das 2007; de Souza 2009; Foyaca-Sibat
2001; Garcia 2004; Gogia 2003; Kalra 2003; Khurana 2012; Singhi
2004; Sotelo 1988), and to participants receiving the intervention
only in four studies (Alarcon 2001; Baranwal 1998; Carpio 2008;
Singhi 2000). One study continued antiepileptic medication if
participants suIering from seizures had already started treatment
(Padma 1995), and one study made no mention of antiepileptics
(Padma 1994). The antiepileptics used are described in Table 2.
Follow-up
All included studies had follow-up points within 12 months of
recruitment. Seven studies included longer-term follow-up past 12
months (Alarcon 2001; Baranwal 1998; Carpio 2008; Das 2007; de
Souza 2009; Garcia 2004; Singhi 2004). Table 3 summarizes follow-
up points for each included trial, stratified by short term (up to 12
months) and long term (> 12 months) follow-up.
Outcome measures
Twelve studies reported seizure recurrence as an outcome. Ten
of these studies had data that could be included in meta-
analysis (Alarcon 2001; Baranwal 1998; Carpio 2008; Chaurasia
2010; Das 2007; Garcia 2004; Gogia 2003; Kalra 2003; Khurana 2012;
Singhi 2004); the remaining two studies reported data on seizure
recurrence suitable for discussion only (de Souza 2009; Foyaca-
Sibat 2001).
Thirteen studies reported complete radiological clearance of
lesions as an outcome, all of which had data that could be
included in meta-analysis (Alarcon 2001; Baranwal 1998; Carpio
2008; Chaurasia 2010; Das 2007; de Souza 2009; Garcia 2004; Gogia
2003; Kalra 2003; Khurana 2012; Singhi 2000; Singhi 2004; Sotelo
1988). Eleven studies reported evolution of cysts as an outcome,
six of which had data that could be included in meta-analysis
(Baranwal 1998; Carpio 2008; Chaurasia 2010; Gogia 2003; Khurana
2012; Padma 1994), whilst the remaining five included studies
reported data on evolution of cysts suitable for discussion only (Das
2007; de Souza 2009; Garcia 2004; Kalra 2003; Singhi 2000).
Table 4 summarizes the specific outcomes reported in each trial,
according to reporting of seizure occurrence/pattern, reporting
of additional health status indicators, reporting of radiological
findings, and reporting of adverse events.
Excluded studies
The reasons for exclusion of the 18 excluded studies are provided
in the Characteristics of excluded studies table. Eleven of these
were identified by the database search and excluded on full-text
assessment as previously discussed. Other studies identified by the
database search and excluded through title/abstract screening are
not included in the table.
An additional seven studies which were included in previous
versions of this review, Abba 2010; Salinas 1999, but excluded
at title/abstract screening in this version, as they compared
anthelmintic treatment regimens without a supportive treatment
comparison group, are also described in Characteristics of excluded
studies. This was the result of a change in the comparison
definitions for this version of the review (Appendix 2); a total of
eight studies included in previous citations of this review were not
included in this version of the review for this reason (Alarcon 1989;
Cruz 1995; Del Brutto 1999; Garcia 1997; Gongora-Rivera 2006; Kaur
2009; Singhi 2003; Sotelo 1990).
Risk of bias in included studies
A 'Risk of bias' table is provided for each included study in the
Characteristics of included studies section. The results of the 'Risk
of bias' assessment are summarized across all included trials in
Figure 3 and Figure 4.
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Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
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Low risk of bias Unclear risk of bias High risk of bias
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Alarcon 2001 ? ? - + + + +
Baranwal 1998 + + + + + + +
Carpio 2008 + + + + + + +
Chaurasia 2010 + ? + + + + +
Das 2007 ? ? ? ? + + +
de Souza 2009 + ? - + + + +
Foyaca-Sibat 2001 + ? + + - + +
Garcia 2004 + + + + + + +
Gogia 2003 + + + + + + +
Kalra 2003 + + - - - + +
Khurana 2012 + ? - - + + +
Padma 1994 ? ? + + + + +
Padma 1995 ? ? + + + + +
Singhi 2000 ? ? - - - + +
Singhi 2004 + ? - + ? + +
Sotelo 1988 ? ? - - + + +
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Allocation
Ten included studies reported adequate methods
of randomization, employing computer-generated number
sequences or random number tables, and were assessed as being
at a low risk of bias (Baranwal 1998; Carpio 2008; Chaurasia 2010; de
Souza 2009; Foyaca-Sibat 2001; Garcia 2004; Gogia 2003; Kalra 2003;
Khurana 2012; Singhi 2004). The remaining studies did not report
the method of randomization and were assessed as at unclear risk
of bias.
Five studies reported adequate allocation concealment and were
assessed as being at a low risk of bias (Baranwal 1998; Carpio
2008; Garcia 2004; Gogia 2003; Kalra 2003), whilst the remaining
studies did not clearly describe allocation concealment methods
and were judged as at unclear risk of bias. All of the included studies
that adequately reported allocation concealment also reported an
adequate method of randomization. No trials were excluded as part
of a sensitivity analysis due to allocation, as none of the included
studies were assessed as being at high risk of bias.
Blinding
Eight included studies reported adequate blinding of participants,
research staI, and outcome reporting clinicians (Baranwal 1998;
Carpio 2008; Chaurasia 2010; Foyaca-Sibat 2001; Garcia 2004;
Gogia 2003; Padma 1994; Padma 1995). In three studies, clinicians
reporting radiological outcomes were described as blinded,
but participants and research staI receiving/administering the
intervention or placebo/control, or both, were not blinded (Alarcon
2001; de Souza 2009; Singhi 2004). We judged each of these studies
as at high risk of performance bias. We considered radiological
outcomes as at low risk and seizure status outcomes as at high risk
of detection bias.
Four included studies were unblinded and assessed as being at
a high risk of both performance and detection bias (Kalra 2003;
Khurana 2012; Singhi 2000; Sotelo 1988). One included study did
not describe blinding methods, and was therefore assessed as
having an unclear risk of both performance and detection bias (Das
2007).
Incomplete outcome data
Eleven included studies reported data from over 85% of their
randomized participants and were assessed as at low risk of
attrition bias (Alarcon 2001; Baranwal 1998; Carpio 2008; Chaurasia
2010; Das 2007; Garcia 2004; Gogia 2003; Khurana 2012; Padma
1994; Padma 1995; Sotelo 1988). de Souza 2009 reported data for
84% of randomized participants and was considered as at low risk
of attrition bias aOer assessment of their reporting, whilst Singhi
2004 reported data for 83% of randomized participants and was
assessed as having an unclear risk of attrition bias.
Three included studies reported data on fewer than 80% of
randomized participants and were assessed as being at high
risk of attrition bias: data were reported for 79% of randomized
participants in Foyaca-Sibat 2001, 75% of randomized participants
in Kalra 2003, and 46% of randomized participants in Singhi 2000.
Selective reporting
We did not detect any selective reporting in the 16 included studies,
although we did not have access to original protocols. Trials with
data reported by several articles, some of which spanned a number
of years, correlated without discrepancy.
Other potential sources of bias
We did not detect any significant additional sources of bias within
the included studies. All trials based the inclusion of participants
on a radiological diagnosis of neurocysticercosis and, if reporting
of seizure outcomes was planned, the presence of seizures in a
defined time frame prior to recruitment.
Regarding publication bias, Figure 5 is a funnel plot for seizure
recurrence (the primary outcome with the largest number of
contributing studies); values below one favoured albendazole.
Figure 6 is a further funnel plot for complete radiological clearance
of lesions (the overall outcome with the largest number of
contributing studies); values above one favoured albendazole.
There was no obvious evidence of publication bias through
asymmetry, though the number of included trials was low.
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Figure 5.   Funnel plot of comparison: 1 Albendazole versus placebo or no anthelmintic, outcome: 1.1 Seizure
recurrence.
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Figure 6.   Funnel plot of comparison: 1 Albendazole versus placebo or no anthelmintic, outcome: 1.12 Complete
radiological clearance of lesions.










See: Summary of findings 1 Albendazole compared with placebo
or no anthelmintics for people with neurocysticercosis
Comparison: albendazole versus placebo or no anthelmintic
Outcome of interest: seizure status at follow-up
Recurrence of seizures
Ten included studies reported on the recurrence of seizures
(Figure 7). Heterogeneity of these studies with regard to
participant recruitment criteria is shown in  Figure 2.  Alarcon
2001 and Garcia 2004 exclusively included participants with viable
cysts; Carpio 2008 and Das 2007 included participants with viable
or non-viable cysts, or both, and all other studies included
participants exclusively with non-viable cysts. With regard to the
anatomical position of cysts, Carpio 2008 and Das 2007  included
participants with extraparenchymal cysts, whilst all other studies
included participants with intraparenchymal cysts only. Baranwal
1998,  Gogia 2003,  Kalra 2003, and  Singhi 2004  only included
children (< 16 years); Das 2007 and Garcia 2004 only included adults
(≥ 16 years); and the remaining studies included both children and
adults. There was substantial heterogeneity, with an I2 statistic of
67%. Subgroup analyses of this outcome are discussed below.
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Heterogeneity: Chi² = 26.99, df = 9 (P = 0.001); I² = 67%
Test for overall effect: Z = 0.61 (P = 0.54)
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Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias
 
Overall, there was no evidence of benefit or harm of albendazole
versus placebo or no anthelmintic (risk ratio (RR) 0.94,
95% confidence interval (CI) 0.78 to 1.14; 10 trials, 1054
participants; Analysis 1.1).
A further included study,  de Souza 2009, reported no significant
diIerence in months seizure-free at the end of follow-up for
participants administered albendazole (22.2 months, 95% CI 6.4 to
38.0; 50 participants) and those who did not receive an anthelmintic
(27.9 months, 95% CI 12.3 to 43.5; 53 participants). We did not
include these data in the meta-analysis as they were not in a
comparable format.
The denominator from the albendazole intervention arm of  Das
2007  diIered slightly (150 versus 148) to a previous version of
this review (Abba 2010), as two participants that died within the
first three months of follow-up were included. This was because
the follow-up point of data extraction was three months. The
numerator and denominator from the no-anthelmintic comparison
arm of  Singhi 2004  diIered to a previous version of this review
(Abba 2010), as data were extracted for participants prior to
stopping of antiepileptic medication. The origin of the previous
values in Abba 2010 are unclear from the article; however, they are
not relevant to this version of the review.
Seizure recurrence aLer withdrawal of antiepileptics
One included study described seizure recurrence in participants
aOer stopping of antiepileptics. Singhi 2004 reported no significant
diIerence in recurrence of seizures in 2/37 (5.4%) participants
receiving albendazole alone, 2/35 (5.7%) participants receiving
albendazole and corticosteroids, and 3/38 (7.9%) participants
receiving corticosteroids alone.
Time to seizure remission
One included study,  de Souza 2009, reported the time taken
for participants to become seizure-free; participants administered
albendazole became seizure-free aOer a mean of 6 months (95%
CI −5.9 to 17.9; 50 participants), whereas participants that did
not receive an anthelmintic became seizure-free aOer a mean of
5.3 months (95% CI −6.3 to 16.9; 53 participants). The diIerence
between these findings was not significant.
Frequency of seizures
Two included studies reported on the frequency of seizures as
an outcome (Carpio 2008; Garcia 2004).  Carpio 2008  reported
a reduction in seizure frequency at 12 months in participants
with generalized seizures who received albendazole compared to
participants who received placebo (adjusted RR 0.21, 95% CI 0.04 to
0.96). The study was not powered suIiciently to support a reduction
in seizure frequency at 24 months (adjusted RR 0.13, 95% CI 0.01 to
1.39). There was no diIerence for participants with focal seizures at
24 months (adjusted RR 3.96, 95% CI 0.54 to 26.28).
Garcia 2004 also reported findings for participants with generalized
and focal (partial) seizures. A reduction in seizure frequency was
reported at 30 months of follow-up in participants with generalized
seizures who received albendazole compared to participants who
received placebo (adjusted RR 0.33, 95% CI 0.16 to 0.68). There
was no diIerence for participants with partial seizures (adjusted RR
0.66, 95% CI 0.24 to 1.79).
Seizure definitions and follow-up periods diIered significantly
between these two studies, therefore data were not subjected to
meta-analysis.
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Sensitivity analysis: seizure status at follow-up
We excluded studies with an unclear risk of bias for allocation
concealment from a sensitivity analysis of seizure recurrence
(Alarcon 2001; Chaurasia 2010; Das 2007), which showed an
apparent benefit of albendazole versus placebo or no anthelmintic
(RR 0.71, 95% CI 0.57 to 0.88; 7 trials, 629 participants; I2 = 50%). As
none of the excluded studies had a high risk of selection bias (only
unclear risk), and moderate heterogeneity remained, we have not
reported this sensitivity analysis as the main results of this review.
It is important to note that  Das 2007  was one of the excluded
studies in this sensitivity analysis, which is a large study that
introduced considerable heterogeneity to the meta-analysis by
including adult participants with multiple cysts only, with mixed
viability and mixed anatomical position (intraparenchymal and
extraparenchymal). When purposefully removed from the primary
analysis, there was evidence of benefit of albendazole versus
placebo or no anthelmintic (RR 0.73, 95% CI 0.59 to 0.91; 9 trials,
754 participants). The I2 statistic with Das 2007 removed from the
analysis was 39%.
Although  Das 2007  was assessed as at unclear risk of selection,
performance, and detection bias, no 'Risk of bias' domain was
assessed as high risk for this study, therefore we have continued
to include it in our main analysis, given that it meets our inclusion
criteria and we cannot justify exclusion based on bias assessment.
Given the heterogeneity of participants,  Das 2007  could not be
included in the majority of subgroup analyses.
Subgroup analyses of note: seizure status at follow-up
Subgroup analysis for the recurrence of seizures was conducted,
and the results for stratification by number of cysts (single versus
multiple) are presented in detail below. A brief description of other
subgroup analyses is also included. It should be noted that all
studies that presented data from participants with a single cyst did
so for participants with non-viable intraparenchymal cysts.
Recurrence of seizures: participants with a single cyst
Five studies reported data from participants with a single
cyst (Figure 8).  Baranwal 1998,  Khurana 2012, and  Singhi
2004  included only children (< 16 years) with single, non-
viable intraparenchymal cysts, whereas Chaurasia 2010 and Gogia
2003  included participants of all ages with single, non-viable
intraparenchymal cysts. There was low heterogeneity (I2 = 16%).
 
Figure 8.   Forest plot of comparison: 1 Albendazole versus placebo or no anthelmintic, outcome: 1.2 Seizure
recurrence subgroup analysis: number of cysts.
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Risk of bias legend
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(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias
 
Overall, the direction of eIect indicated a benefit of albendazole
versus placebo or no anthelmintic (RR 0.61, 95% CI 0.4 to 0.91;
5 trials, 396 participants;  Analysis 1.2). As described above, all
participants included in this analysis had non-viable cysts.
Recurrence of seizures: participants with multiple (> 1) cysts
Two studies reported data from participants with multiple cysts
(Figure 8). Das 2007 included participants with viable or non-viable
cysts, or both, regardless of intraparenchymal/extraparenchymal
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position anatomically, whereas Gogia 2003  included participants
with non-viable intraparenchymal cysts only. Both studies included
participants of all ages. There was substantial heterogeneity (I2 =
64%).
Overall, the direction of eIect indicated a possible harm of
albendazole versus placebo or no anthelmintic (RR 2.05, 95% CI
1.28 to 3.31; 2 trials, 321 participants; Analysis 1.2).
Recurrence of seizures: other subgroup analyses
Stratification by cyst viability: there was no evidence of benefit
or harm of albendazole versus placebo or no anthelmintic for
participants with viable cysts (RR 0.91, 95% CI 0.62 to 1.33; 2 trials,
174 participants; Analysis 1.3). There was low heterogeneity (I2 =
0%). For participants with non-viable cysts, there was evidence of a
benefit of albendazole versus placebo or no anthelmintic (RR 0.55,
95% CI 0.38 to 0.78; 6 trials, 507 participants; Analysis 1.3). There
was low heterogeneity (I2 = 5%).
Stratification by anatomical position of cysts: there was evidence
of a benefit of albendazole versus placebo or no anthelmintic for
participants with intraparenchymal cysts (RR 0.66, 95% CI 0.51 to
0.86; 8 trials, 681 participants; Analysis 1.4). There was moderate
heterogeneity (I2 = 20%). No studies recruited participants with
extraparenchymal cysts only.
Stratification by participant age (children/adults): there was
evidence of a benefit of albendazole versus placebo or no
anthelmintic for participants under 16 years of age (RR 0.46, 95%
CI 0.30 to 0.69; 4 trials, 335 participants;  Analysis 1.5). There
was low heterogeneity (I2 = 0%). Two studies that recruited
adult participants showed evidence of harm of albendazole
versus placebo (RR 1.45, 95% CI 1.06 to 1.98; 2 trials, 416
participants; Analysis 1.5). Das 2007 was included in this analysis of
adults, and likely contributed to the high heterogeneity (I2 = 89%).
Stratification by corticosteroid administration: there was no
evidence of benefit or harm of albendazole versus placebo or no
anthelmintic for participants with the same corticosteroid regimen
given to all participants (RR 0.83, 95% CI 0.61 to 1.13; 3 trials,
208 participants;  Analysis 1.6). There was also no evidence of
benefit or harm of albendazole versus placebo or no anthelmintic
for participants receiving no corticosteroids (RR 0.97, 95% CI
0.50 to 1.88; 3 trials, 230 participants;  Analysis 1.6). There was
low heterogeneity in both analyses, with an I2 statistic of 9%
and 0%, respectively. We did not include studies in which the
corticosteroid regimen diIered between albendazole and placebo
or no anthelmintics groups in these analyses.
Outcomes of interest: secondary health status indicators at
follow-up
Death (any cause)
Two included studies reported deaths (Carpio 2008; Das 2007). Four
of 234 (1.7%) participants in the albendazole group and 5 of 236
(2.1%) participants in the placebo group from these trials died
during follow-up of two to five years, with no significant diIerence
between albendazole and placebo treatment groups (Analysis 1.7).
Hospital admission (any cause)
One included study reported hospital admissions, following up
participants for five years aOer enrolment (Das 2007). Data were
extractable for analysis at three months (Analysis 1.8), during which
time participants treated with albendazole had a higher risk of
hospital admission (RR 2.50, 95% CI 1.52 to 4.11; 300 participants).
At two, three, four, and five years of follow-up, there was no
significant diIerence in hospital admission between participants
that received albendazole or placebo at enrolment.
Headache
Two included studies reported headache as an outcome (Carpio
2008; Das 2007).  Carpio 2008  reported that within the first 12
months of treatment, 74/79 (93.7%) of participants who received
albendazole reported headache, and 78/82 (95.1%) of participants
who received placebo reported headache, with no significant
diIerence between groups (Analysis 1.9). In this trial, of the 173
participants initially recruited, 124 (71.7%) reported headache at
baseline, with no diIerence between the albendazole arm (60/88)
and the placebo arm (64/90).
Das 2007  reported encephalopathy (defined as vomiting/
headache/altered sensorium) in participants over five years,
though due to the presentation of these data, reliable extraction
was only possible at three months: 45/148 (30.4%) participants
receiving albendazole and 15/150 (10%) participants receiving
placebo reported symptoms of encephalopathy. This diIerence
was significant, despite the exclusion of two participants from
the albendazole arm prior to analysis who reportedly died from
intractable seizures and severe encephalopathy during this period.
Headache-specific data were not reported and therefore not
available for meta-analysis.
Signs of focal neurological deficit
One included study reported data for signs of focal neurological
involvement (Carpio 2008). Limb weakness/gait disturbance were
the symptoms/signs captured: there was no diIerence between
these signs/symptoms in participants who received albendazole
and those who received placebo at 12 months (RR 0.89, 95% CI 0.65
to 1.23; 161 participants; Analysis 1.10).
Surgical intervention
One included study reported surgical intervention (Alarcon
2001). One event was reported amongst participants receiving
albendazole, and none amongst participants who did not receive
albendazole (RR 1.64, 95% CI 0.07 to 38.94; 83 participants; Analysis
1.11).
Resolution of symptoms/resumption of normal activities
These outcomes were not addressed by any of the included studies.
Outcomes of interest: radiological findings at follow-up
Complete radiological clearance of lesions
Thirteen included studies reported lesions resolving completely
(Figure 9). Data were extracted at the participant level (as per our
protocol), not at the lesion level. Figure 2 depicts the heterogeneity
of the recruitment criteria of these trials.  Alarcon 2001,  Garcia
2004, and Sotelo 1988 exclusively included participants with viable
cysts; Carpio 2008 and Das 2007 included participants with viable
or non-viable cysts, or both; and the other studies included
participants exclusively with non-viable cysts. Carpio 2008 and Das
2007  included participants with extraparenchymal cysts, whilst
the other studies included participants with intraparenchymal
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cysts only.  Baranwal 1998,  Gogia 2003,  Kalra 2003,  Singhi 2000,
and  Singhi 2004  only included children (< 16 years), whilst  Das
2007, Garcia 2004, and Sotelo 1988 only included adults (≥ 16 years).
All of the remaining studies included both children and adults.
There was substantial heterogeneity (I2 = 70%).
 
Figure 9.   Forest plot of comparison: 1 Albendazole versus placebo or no anthelmintic, outcome: 1.12 Complete

















Heterogeneity: Chi² = 39.54, df = 12 (P < 0.0001); I² = 70%
Test for overall effect: Z = 2.98 (P = 0.003)















































































M-H, Fixed, 95% CI
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Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias
 
Overall, the direction of eIect indicated a benefit of albendazole
versus placebo or no anthelmintic (RR 1.22, 95% CI 1.07 to 1.39; 13
trials, 1324 participants; Analysis 1.12).
The numerators from the albendazole intervention and placebo
comparison arms of Das 2007 diIered to a previous version of this
review (Abba 2010), as data were extracted at 12 months of follow-
up rather than three.
Reduction of number of lesions
Three included studies reported a reduction of the number of
lesions. Sotelo 1988 recruited adult participants (≥ 16 years) with
viable, intraparenchymal cysts. Carpio 2008 and Padma 1995 both
recruited participants of any age, with viable or non-viable cysts, or
both, irrespective of intraparenchymal/extraparenchymal position
anatomically. There was moderate heterogeneity (I2 = 45%).
Studies that exclusively recruited participants with a single cyst
were not included in this analysis, as these data were more
appropriately interpreted as a complete radiological clearance of
lesions (Analysis 1.12).
Overall, the direction of eIect indicated no benefit or harm of
albendazole versus placebo or no anthelmintic (RR 1.33, 95% CI
0.89 to 1.98; 3 trials, 115 participants; Analysis 1.13).
Evolution of cysts
Six included studies reported the evolution of cysts in a manner
that could be extracted for meta-analysis (Figure 10).  Baranwal
1998  and  Gogia 2003  recruited children (< 16 years) with non-
viable, intraparenchymal cysts only.  Chaurasia 2010,  Khurana
2012, and  Padma 1994  also recruited participants exclusively
with non-viable, intraparenchymal cysts, but of any age.  Carpio
2008  recruited participants of any age, with viable or non-viable
cysts, or both, irrespective of intraparenchymal/extraparenchymal
position anatomically. There was very low heterogeneity (I2 = 0%).
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Heterogeneity: Chi² = 4.10, df = 5 (P = 0.53); I² = 0%
Test for overall effect: Z = 3.18 (P = 0.001)
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Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias
 
Overall, the direction of eIect indicated a benefit of albendazole
versus placebo or no anthelmintic (RR 1.27, 95% CI 1.10 to 1.47; 6
trials, 434 participants; Analysis 1.14).
Several studies reported evolution of cysts in a manner that could
not be extracted for meta-analysis. de Souza 2009 reported a more
detailed sequence of degeneration at lesion-level, with non-viable
enhancing cysts considered separately at early and late stages
(outside of the scope of this review).  Garcia 2004  also reported
evolution of cysts at lesion-level: when considering viable cysts,
79/192 (41.1%) of cysts from participants receiving albendazole
persisted unchanged, compared to 243/279 (87.1%) of viable cysts
from participants who received placebo (RR 2.12, 95% CI 1.59
to 2.81; 471 cysts).  Kalra 2003  reported participant-level partial
resolution or calcification of cysts in 37/47 (78.7%) of participants
who received albendazole and 26/46 (56.5%) of participants who
did not receive albendazole (odds ratio 3.1, 95% CI 1.2 to 7.9;
93 participants). These data could not be extracted, as "partial
resolution" was not defined. All participants were children (< 16
years) with one or two cysts on enrolment. Singhi 2000  reported
an "improvement in lesion" (disappearance or reduction in size)
at participant-level in 82/90 (91.1%) of participants with a single
cyst who received albendazole and had a follow-up CT aOer three
months, compared to 73/86 (84.9%) of participants with a single
cyst who did not receive albendazole. It should also be noted that
these 176 participants were selected for this analysis because they
had a single non-viable cysts and also received a follow-up CT;
380 participants with a single cyst were originally enrolled in the
trial. Finally, Das 2007  reported participant-level data on "partial
resolution" of cysts at three months, six months, 12 months, and
then yearly to five years. It appears that their data were not
cumulative, therefore it is likely that each follow-up point reports
the change since the last follow-up, with CT scans every six months
in participants with residual lesions. The denominator is therefore
diIicult to confirm. At 12 months, 65/148 (43.9%) of participants
who received albendazole were reported to have partial resolution
of their cysts, compared to 60/150 (40%) of participants who
received placebo. No statistical analyses were performed on these
data, due to the denominator uncertainty.
Radiological resolution/development of oedema
One included study reported data regarding the resolution and
development of oedema (Padma 1995). In this small study, 12/16
(75%) participants who received albendazole had improvement
of oedema on CT compared to 11/13 (84.6%) participants who
received placebo at three months (Analysis 1.15), with no
significant diIerence between groups. In the same population
there was one instance of worsening oedema in both the
albendazole and placebo arms (Analysis 1.16). Based on the report
of this study, the administration of corticosteroids is unclear.
Radiological resolution/development of raised intracranial pressure
These outcomes were not addressed by any of the included studies.
Subgroup analyses of note: radiological findings at follow-up
Complete radiological clearance of lesions
Stratification by cyst viability: evidence of benefit of albendazole
versus placebo or no anthelmintic persisted for participants with
viable cysts (RR 2.52, 95% CI 1.65 to 3.85; 3 trials, 207 participants; I2
= 0%) and participants with non-viable cysts (RR 1.22, 95% CI 1.05 to
1.41; 8 trials, 748 participants; I2 = 62%), with lower heterogeneity
in the evidence for participants with viable cysts. (Analysis 1.17)
Outcomes of interest: adverse events associated with treatment
(side e"ects) at follow-up
Frequency and nature of adverse events
Seven included studies explicitly mentioned the frequency and
nature of adverse events. The frequency of adverse events
varied depending on how they were reported, and could not
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be incorporated into a meta-analysis due to the nature of this
reporting and the varying definitions between trials.
Chaurasia 2010  and  Khurana 2012  each reported very few
events, each with only a single episode of benzodiazepine-
associated rash that resolved aOer cessation of the oIending
medication. No adverse events or side eIects attributable
to albendazole administration were reported. Neither study
administered corticosteroids to participants of either group.
Carpio 2008,  Garcia 2004, and  Kalra 2003  each reported
common adverse events and side eIects, observed in all
participants.  Carpio 2008  reported seizures, headache, and
gastrointestinal complications (nausea, abdominal pain, or
vomiting) in the first month of follow-up comparing the rates
between participants receiving albendazole or placebo (P = 0.64,
0.95 and 0.38 respectively). Three participants in the placebo
group had intracranial hypertension within the first eight days of
treatment. Garcia 2004 reported seizure, headache, paraesthenia,
paresis, dizziness, abdominal pain, nausea, diarrhoea, and rash
as separate side eIects in participants who received albendazole
or placebo. Only abdominal pain diIered between the two
groups, favouring no anthelmintic (P = 0.006). For all other
comparisons, P ≥ 0.2. Three additional adverse events were
reported, all in the placebo group and all likely unrelated to
neurocysticercosis (seizures during hyperemesis of pregnancy,
arteriovenous malformation bleed, and gastric malignancy). Kalra
2003  reported headache, vomiting, and visual disturbance in the
first 15 days of treatment, with no significant diIerence between
the albendazole and no-anthelmintic arms of the trial. Data were
not provided. All of these studies had a corticosteroid regimen that
varied between participants receiving albendazole and those who
received placebo or no anthelmintic, so it is diIicult to determine
whether corticosteroids improved or worsened the frequency or
nature of adverse events.
Alarcon 2001 and Sotelo 1988 only presented data for participants
who received an anthelmintic.  Alarcon 2001  reported that 8/27
(29.6%) of participants receiving albendazole for three days and
6/27 (22.2%) of participants receiving albendazole for eight days
reported a headache. Data from the 29 participants who did
not receive albendazole are not discussed. Of the participants
who received albendazole, 14/54 (25.9%) reported vomiting
or dizziness. Each albendazole duration group reported one
participant that suIered from a seizure and one participant that
suIered from a focal motor deficit. Sotelo 1988 pooled data from
the 10 participants in the albendazole arm and 10 participants
in the praziquantel arm of the trial: 14/20 (70%) suIered from
headache, 9/20 (45%) nausea, 6/20 (30%) vomiting, 4/20 (20%)
hyperthermia, 3/20 (15%) seizure, 2/20 (10%) somnolence, 1/20
(5%) diplopia, and 1/20 (5%) transient hemiparesis.
Adverse events requiring withdrawal of anthelmintics
None of the included studies reported an adverse event in any of
their participants requiring withdrawal of treatment.
Comparison: praziquantel versus placebo or no anthelmintic
Two studies evaluated praziquantel as an intervention, comparing
its use to no anthelmintic. The data from each study were either
from very small populations or not presented in an extractable
form, and therefore have not been included in further meta-
analysis.
Outcome of interest: seizure status at follow-up
Foyaca-Sibat 2001  presented data for 143 participants with
neurocysticercosis and recurrent seizures, who were recruited from
a population where most participants also had HIV, pulmonary
tuberculosis, and/or urinary schistosomiasis. Of the participants
for which data were presented, 71 received praziquantel,
prednisolone, and phenytoin, and 72 received phenytoin alone.
Results were presented as statistical analysis on an ordinal scale
of seizure response in four categories, devised by the institution
in which the study took place and not extractable, therefore these
data were not considered for further analysis. Based on the graphs
presented, most participants who received praziquantel had either
resolution of seizures or reduced seizure duration and frequency.
Most participants who received phenytoin alone had no change in
their symptoms or reduced seizure frequency alone.
Outcomes of interest: radiological findings at follow-up
Sotelo 1988  was a small study comparing 10 participants who
received praziquantel to five participants who did not receive an
anthelmintic. Of the 10 participants who received praziquantel,
seven had complete radiological clearance of lesions; two had a
reduction in the number of lesions; and one had no change in
the number of lesions. Of the five participants who received no
anthelmintic, five had no change in the number of lesions. Sotelo
1988 also reported data from 10 participants who were randomized
to receive albendazole (included in  Analysis 1.12  and  Analysis
1.13 and discussed previously).
Outcomes of interest: adverse events associated with treatment
(side e"ects) at follow-up
Some of the potential adverse events or side eIects from
praziquantel administration, pooled with data from participants
receiving albendazole (Sotelo 1988), are discussed above.
D I S C U S S I O N
Summary of main results
Findings for the most reported primary outcome of interest (seizure
recurrence), including subgroup analysis by number of cysts,
and two secondary outcomes (complete radiological clearance of
lesions and evolution of cysts and adverse events), are presented
in Summary of findings 1.
The results of studies comparing anthelmintic treatment with
no anthelmintic were mixed and therefore diIicult to interpret;
recruitment criteria diIered greatly between trials, including the
number of cysts per participant, cyst viability, cyst anatomical
position, and participant age. There is substantial heterogeneity in
most comparisons as a result. Almost all of the included studies
assessed albendazole; we found only two studies comparing
praziquantel with no active treatment, from which we could not
draw any meaningful conclusions on its eIicacy.
Overall, albendazole probably makes little or no diIerence
to seizure recurrence (low-certainty evidence) compared to no
anthelmintic. However, when considering the analysis stratified by
number of cysts (single/multiple), there is probably a reduction
of seizure reduction for participants with a single cyst (moderate-
certainty evidence). For participants with multiple cysts, we are
uncertain as to whether albendazole reduces seizure recurrence,
as the evidence is of very low certainty for this group. Studies
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contributing to the single cyst subgroup analysis only included
participants with non-viable intraparenchymal cysts, and most only
recruited children, whereas studies contributing to the multiple
cysts subgroup included participants with viable and non-viable
cysts, both intraparenchymal and extraparenchymal.
With regard to radiological findings, albendazole probably
improves complete radiological clearance of lesions and evolution
of cysts, with moderate-certainty evidence. These findings were
conserved with stratification by cyst viability.
Seizure recurrence
For seizure recurrence, most studies individually trended towards
a benefit of albendazole, though the pooled analysis showed no
evidence to support benefit or harm, with low-certainty evidence.
One study in particular, Das 2007, favoured no anthelmintic, and,
as the largest study of the analysis, this finding had a large eIect
on the pooled results. It should be noted that Das 2007 recruited
participants of any age, with multiple cysts of any viability or
anatomical position (Figure 2), and also had an unclear risk of
bias in three categories (random sequence generation, allocation
concealment, and blinding). As such, its inclusion in the analysis
contributed to an assessment of low-certainty evidence for this
outcome. However, we could not justify its exclusion from the
analysis, given that its exclusion did not significantly improve the
heterogeneity between studies, and there was no 'Risk of bias'
domain that suggested a high risk.
Analysis was stratified by number of cysts, revealing that for
participants with a single cyst, there was a probable benefit of
albendazole compared to that of no anthelmintic, with moderate-
certainty evidence. For participants with multiple cysts, the pooled
evidence was of very low certainty, therefore we are uncertain
whether albendazole reduces seizure recurrence for people with
multiple cysts, though the trend of the findings was towards a
detriment/harm of albendazole versus placebo or no anthelmintic.
It is important to note the low heterogeneity between studies
recruiting participants with single cysts (Figure 2), likely because all
studies recruited participants with non-viable, intraparenchymal
cysts, and most studies (three out of five) only recruited children.
As a result, stratification by cyst viability (viable versus non-
viable) and age (< 16 years versus ≥ 16 years) showed a similar
trend to stratification by number of cysts (single versus multiple).
Stratification by number of cysts was chosen for analysis as
it has the strongest biological plausibility: summative burden
of neurocysticerci could impact on the benefit or harm of
anthelmintic treatment depending on the number of cysts, given
that administration could lead to a co-ordinated parasite death and
degradation, and therefore a detrimental immune response with
increased inflammation and oedema, in participants with multiple
cysts.
Given that the meta-analysis of data from participants with a
single cyst exclusively includes participants with a non-viable
intraparenchymal cyst, the results should be interpreted with
caution. Unfortunately, data for single viable cysts are lacking
from the studies identified by this review for comparison. Any
data available for viable cysts are complicated by substantial
heterogeneity between participants and low-certainty evidence,
and as such are diIicult to interpret (Figure 2). The fact that a
significant eIect of albendazole is observed in a population with
a single non-viable cyst may be considered counterintuitive, given
the consensus that these cysts are already non-viable. Degradation,
however, takes months to years (a dying parasite rather than a dead
parasite, both of which can appear as a non-viable cyst), and it
is plausible that treatment with anthelmintics could hasten this
process.
Complete radiological clearance of lesions
For complete radiological clearance of lesions, there was evidence
of a probable benefit of albendazole compared to placebo
or no anthelmintic. Data contributing to this finding were all
from follow-up within 12 months of treatment. For data to
be included into the analysis for this outcome, all lesions
at participant-level must have resolved completely and not
calcified. One study,  Das 2007, reported results that suggested
a reduction in complete radiological clearance in participants
receiving albendazole compared to placebo, though it must be
noted that this is one of the few studies that recruited participants
with two cysts or more (without an upper limit), and as such
included participants with the largest neurocysticerci burden.
Despite the heterogeneity and direction of findings introduced by
the inclusion of  Das 2007, the overall certainty of the evidence
contributing to the pooled analysis was moderate.
Evolution of cysts
For evolution of cysts, there was evidence of a probable benefit
of albendazole compared to placebo or no anthelmintic. Data
contributing to this finding were all from follow-up within 12
months of treatment. The certainty of the evidence contributing
to the pooled analysis was moderate. This outcome intended to
capture the progression of cysts from viable to non-viable and
events of calcification in addition to full radiological clearance,
rather than full radiological clearance alone. All data were extracted
at the participant level, not the lesion level. This limited the number
of studies that could contribute to this outcome, as many studies
reported lesion-level evolution, rather than presenting the data in
such a way that would permit participant-level data extraction.
Adverse events
Participants treated with either albendazole or praziquantel
appeared to experience more adverse events during treatment
than those receiving placebo or no anthelmintic, with the most
commonly reported adverse events or side eIects being headache,
abdominal pain, and nausea/vomiting. Studies reporting adverse
events did so to a varying degree, therefore the frequency and
nature of adverse events and side eIects diIered greatly between
trials. None of the included studies reported an adverse event that
required the withdrawal of treatment.
Overall completeness and applicability of evidence
We identified 16 relevant published studies. Most were published
prior to the last update of this Cochrane Review and were
included previously (Abba 2010). Three studies were new: two were
published aOer the last update (Chaurasia 2010; Khurana 2012), and
one was published prior to it (Foyaca-Sibat 2001). Two studies had
more data available aOer the publication of further manuscripts
since the last update of this review (Carpio 2008; de Souza 2009).
Unpublished data were provided for two studies (Alarcon 2001;
Carpio 2008), aOer corresponding authors were contacted to clarify
stratification between populations. All of the included studies were
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small: the largest enrolled 300 participants, and the smallest 25
participants.
This review does not fully represent the geographical burden of
neurocysticercosis. All studies were based in Central and South
America and South-East Asia, apart from one study from South
Africa (Foyaca-Sibat 2001), which could only be included in the
results narrative, rather than the meta-analysis, due to its design
and reporting methods. Consequently, there were no studies
included in the meta-analysis from Africa or China, where T solium
is endemic and neurocysticercosis frequently reported.
The study participants varied, including participants of all ages
and those with diIerent numbers and types of lesion. Studies that
recruited children tended to include participants with a single,
non-viable intraparenchymal cyst, whilst studies that recruited
adults mostly included participants with multiple cysts of varying
viability and anatomical position. This is likely a result of the natural
history of neurocysticercosis: older participants have had more
opportunity for cumulative exposure, leading to multiple cysts at
diIerent stages of progression.
Treatment comparisons of the included studies were wide-ranging,
including varying treatment duration (from 3 to 28 days of
albendazole), the use of placebo or no anthelmintic treatment,
and the concurrent use of corticosteroids for no participants/
all participants/only participants receiving an anthelmintic. The
true frequency of adverse events during treatment was diIicult
to ascertain given the diIerent levels of reporting between
studies. Headache, abdominal pain, nausea and vomiting were
common, however in keeping with the known side eIect profile of
albendazole in the treatment of other helminth infections in clinical
practice.
Of the 16 included studies, 11 reported seizure-related outcomes,
arguably the most important set of outcomes to patients. All
but one of the included studies assessed and reported on the
radiological presence of cysts and their resolution or evolution.
However, this may not directly correlate with the presence or
severity of seizures or other symptoms. Radiological outcomes
specific to neurocysticercosis are easy to assess, though their utility
may be limited clinically.
All of the included studies were small. In addition, considerable
heterogeneity was introduced by one relatively large but poorly
reported study, with results mostly running in the opposite
direction to those reported in other studies (Das 2007). This is
perhaps explained by the study's recruitment criteria (multiple
cysts with mixed viability and anatomical positions), but could also
be due to unclear risk of bias for random sequence generation,
allocation concealment, and blinding. This study was also one of
the few trials that administered corticosteroids in the albendazole
treatment arm but not in the placebo arm. As a result, the certainty
of the evidence to which this study contributed was downgraded
on GRADE assessment.
Quality of the evidence
The risk of bias varied between studies; there appeared to be no
correlation between risk of bias and either the trial size or how
recently the study was conducted. Five studies had a low risk of bias
across all indicators, six had an unclear risk of bias in one to three
indicators, and five had a high risk of bias in one to two indicators,
along with zero to three indicators at unclear risk of bias.
Risk of bias was one of the key GRADE assessment considerations,
along with inconsistency, which resulted in the downgrading of
evidence to low certainty for the outcome seizure recurrence before
stratification. AOer stratifying by number of cysts, risk of bias
and inconsistency continued to be of concern for participants
with multiple cysts, along with indirectness. Together these
considerations resulted in an assessment of very low-certainty
evidence. For participants with a single cyst, imprecision was the
only GRADE consideration of concern, resulting in an assessment of
moderate-certainty evidence. Risk of bias was not a consideration
of concern for the evidence available for this population.
For the outcome complete radiological clearance of lesions,
inconsistency was the only GRADE consideration of concern,
resulting in an assessment of moderate-certainty evidence. For the
outcome evolution of cysts, imprecision was the only consideration
of concern, resulting in an assessment of moderate-certainty
evidence.
Potential biases in the review process
Extraction of data exclusively at the participant level for meta-
analysis in this review may have introduced selective outcome
reporting, but we believe this method of extraction is preferable
to including separate extraction and analyses at lesional-level. A
large proportion of studies contributing to our findings recruited
individuals with a single cyst. Studies that pooled lesional data
could not be included in meta-analysis given our methods, but have
been included in the narrative of the results.
The results aOer stratification by single or multiple cysts for the
analysis of seizure recurrence could be explained by a number
of variables (cyst viability, cyst anatomical position), as studies
contributing to the data for single cysts exclusively recruited
participants with non-viable intraparenchymal cysts. As a result,
the observed low heterogeneity was likely due to multiple factors
contributing to the comparison of more homogenous populations.
We have presented the results and forest plots for all subgroup
stratifications for clarity, leading with number of cysts given the
highest biological plausibility.
Finally, consideration of seizures being equal could have biased
our results. Some studies showed significance in general seizure
improvement that was not present in individuals with focal
seizures. These findings are included in the narrative of our results.
However, most studies reported seizure outcomes without defining
the type of seizure; even if our methods were to have included
stratification by general/focal seizures it would not have changed
our results.
Agreements and disagreements with other studies or
reviews
Our results vary slightly from other recent meta-analyses and
reviews assessing albendazole compared to placebo or no
anthelmintic, but the conclusions reached are similar.
A meta-analysis in children (Mazumdar 2007; four trials, 400
participants) with neurocysticercosis revealed a higher remission
of seizures in those treated with albendazole compared to controls
(RR 1.26, 95% CI 1.09 to 1.46). This agrees with our findings, and
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the four studies were included in our search results. Three of
these studies contribute to our analysis of five trials that recruited
participants with a single non-viable intraparenchymal cyst. The
authors of this review also reviewed 10 observational studies with
varying results. The overall recommendation of this review was
support for the use of albendazole for the treatment of children
with one or two cysts secondary to neurocysticercosis.
Del Brutto 2006 reported a meta-analysis of 11 randomized studies
of participants with neurocysticercosis located in or adjacent to
the cerebral parenchyma. Anthelmintic treatment was associated
with complete radiological clearance of viable cysts (44% versus
19%; P = 0.025) at follow-up. Studies on non-viable cysts showed a
trend towards lesion resolution favouring anthelmintic drugs (72%
versus 63%; P = 0.38), but this was not significant unless an outlying
trial was excluded (69% versus 55%; P = 0.006). In participants
with non-viable cysts, risk for seizure recurrence was lower aOer
anthelmintic treatment (14% versus 37%; P < 0.001). The single
trial evaluating the frequency of seizures in participants with viable
cysts showed a 67% reduction in the rate of generalized seizures
with treatment (P = 0.006). All studies identified by Del Brutto
2006 were included in our literature search; nine contributed to
our review (Alarcon 2001; Baranwal 1998; Garcia 2004; Gogia 2003;
Kalra 2003; Padma 1994; Padma 1995; Singhi 2004; Sotelo 1988),
and two were excluded because there was no supportive treatment
arm for comparison (Alarcon 1989; Carpio 1995).
White 2018 provides updated guidelines for the treatment of
neurocysticercosis by the Infectious Diseases Society of America
(IDSA) and the American Society of Tropical Medicine and
Hygiene (ASTMH). Treatment is recommended for viable cysts, with
monotherapy (albendazole) for one to two cysts and dual therapy
(albendazole and praziquantel) for more than two cysts. Data
from Garcia 2004, included in this review, recruited participants
exclusively with viable cysts and showed a significant reduction in
the numbers of generalized seizures amongst participants. These
findings, along with the data from Carpio 2008, are the main
evidence used in White 2018 for viable cyst recommendations. Our
findings do not provide suIicient evidence to support or dispute
this; data for single viable cysts are lacking, and pooled analyses for
multiple cysts have substantial heterogeneity. However, given the
trend observed that albendazole may be detrimental with regard to
seizure recurrence in participants with multiple cysts (Analysis 1.2),
including participants with viable cysts, advocating anthelmintic
treatment as standard for patients with multiple cysts should
be done with caution. White 2018 advises that corticosteroids
be used whenever anthelmintics are used. This could, in theory,
mitigate the detrimental risk of anthelmintics in patients with
multiple cysts, and our review was not designed to consider
the impact of corticosteroids on anthelmintic administration
specifically in the meta-analysis. However, a trend towards harm
in participants with multiple cysts receiving albendazole was
observed (more seizure recurrence), despite the fact that Das 2007,
the largest study contributing to the meta-analysis for participants
with multiple cysts, administered corticosteroids to participants
receiving albendazole.
The updated IDSA/ASTMH guidelines recommend albendazole
treatment for single enhancing (non-viable) cysts, which is
supported by the results of this review, and no treatment for
calcified lesions alone. Extraparenchymal cysts should be treated
on a case-by-case basis, with the focus of therapy centred
around neuroendoscopy, cerebrospinal fluid diversion, or other
surgical managements depending on the anatomical nature of
the cyst. Given the heterogeneity introduced by the inclusion of
Das 2007, a large study that included both intraparenchymal and
extraparenchymal cysts, it could be that the inclusion of such
complex patients impacted on the results of this trial.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
For participants presenting with seizures, the evidence suggests a
benefit of albendazole for those with a single cyst, with a reduction
in seizure recurrence. The evidence supporting this is of moderate
certainty and is exclusively from studies that recruited participants
with non-viable intraparenchymal cysts, with a large proportion
of participants being children (< 16 years). Evidence of benefit or
harm of albendazole treatment for participants with more than
one cyst is lacking, due in part to few studies reporting on such
populations, but also to a large trial with very few exclusion criteria
to recruitment, leading to substantial heterogeneity when included
in analysis. That being said, the observed trend in participants
with multiple cysts was that of potential harm from albendazole
treatment, with more seizure recurrence compared to placebo or
no anthelmintic, although the certainty of this evidence is very low.
This review suggests that there is a benefit of albendazole
treatment with regard to complete radiological clearance of
lesions secondary to neurocysticercosis as well as the evolution
of cysts, regardless of viability or participant age. Treatment for
calcified lesions is not recommended. It should also be noted that
radiological abnormalities do not necessarily correlate with clinical
symptoms.
In summary, this review supports the use of albendazole treatment
for patients with a single cyst. For patients with multiple cysts,
there is no strong evidence either way, but our results suggest
that there may be a risk of albendazole causing more harm,
even with corticosteroid adjunctive therapy (there was no clear
diIerence in albendazole eIicacy between studies that did or did
not co-administer corticosteroids to all participants). The current
recommended duration of treatment (14 days -  White 2018) is
longer than the treatment used in many of the studies included in
this review, and requires further consideration, especially as many
patients in the countries in which T solium is endemic are required
to self-fund their health care.
Implications for research
Our initial search identified multiple studies, particularly those
published more recently, which were designed to compare diIerent
anthelmintic drug regimens and/or the addition of corticosteroid
adjunctive therapy to anthelmintic treatment, even though robust
evidence for the benefit of anthelmintic treatment versus no
anthelmintics is lacking. These studies were excluded from our
review, as per our protocol; our focus was on the benefit of
anthelmintics compared to no anthelmintic. As a result, there have
been very few additional randomized controlled trials included in
this review compared to the previous version (Abba 2010). Many
of the additional manuscripts available from our updated search
reported new analyses from studies conducted prior to 2010.
The certainty of evidence supporting the use of anthelmintics
for people with neurocysticercosis is moderate at best. The
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literature would benefit from further randomized controlled trials
(particularly trials that recruit either participants with a single
viable cyst or participants with multiple cysts) to address this
question, central to the management of neurocysticercosis. In
particular, there is a need for larger studies with data reported at
the participant level (rather than the lesion level). The presentation
of data in future studies should aim to allow for the stratification
of participants by cyst number, cyst viability, and cyst anatomical
position in order to support future systematic review and meta-
analyses and permit an exploration of the nature of heterogeneity.
All of these suggestions aim to improve the certainty of evidence
available to support clinical decision-making; at present, none of
the evidence found in this review could be considered of high
certainty.
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Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Type of study: randomized controlled trial
Duration: participants followed up for 12 months (primary outcome) and 24 months (secondary out-
come), recruited between January 1989 and December 1996
Participants Number: 95 enrolled, data available for 83 after exclusions/loss to follow-up (36 male, 47 female)
Inclusion criteria: males and females of all ages, neurological signs and symptoms for between 1 week
and 3 years, 1 to 6 non-enhancing parenchymal cysts on CT
Exclusion criteria: ring-like or nodular enhanced cysts on CT, perilesional oedema, subarachnoid or in-
traventricular cysts, hydrocephalus, previous treatment with albendazole or praziquantel, pregnant
women, and clinical evidence intracranial hypertension
Types of lesion: viable cysts
Position of lesions: intraparenchymal
Number of lesions: 1 to 6
Interventions Group 1. Albendazole: 15 mg/kg daily for 3 days
Group 2. Albendazole: 15 mg/kg daily for 8 days
Group 3. No albendazole
All groups: antiepileptics (symptomatic only)
Outcomes Included in meta-analysis: seizure recurrence (≥ 24 months), surgical intervention (24 months), com-
plete radiological clearance of lesions (12 months)
Included in narrative only: frequency and nature of adverse events
Notes Location: Ecuador
Source of funding: not stated
Risk of bias
Alarcon 2001 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated, but trial described as "randomized".
Allocation concealment
(selection bias)





High risk No placebo used, and no blinding described.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "Evaluation of the number of cysts on CT at baseline and at follow-up





Low risk 95 participants randomized: 8 excluded before starting treatment, 4 lost to fol-
low-up, 83 (87%) included in the analysis.
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting





Methods Type of study: randomized controlled trial
Duration: participants followed up for 15 months, dates not stated
Participants Number: 72 enrolled, data available for 63 after exclusions/loss to follow-up (34 male, 29 female)
Inclusion criteria: children aged 2 to 12 years, focal seizures for < 3 months, "single small enhancing
computerised tomographic lesion" on CT < 20 mm
Exclusion criteria: neurological deficit, suspected tuberculosis
Types of lesion: non-viable cyst
Position of lesions: intraparenchymal
Number of lesions: 1
Interventions Group 1. Albendazole: 15 mg/kg daily in 2 divided doses for 28 days
Group 2. Placebo: identical dextrose capsules for 28 days
All groups: prednisolone (all), antiepileptics (symptomatic only)
Outcomes Included in meta-analysis: seizure recurrence (15 months), complete radiological clearance of lesions
(3 months), evolution of cysts (3 months)
Included in narrative only: frequency and nature of adverse events
Baranwal 1998 
Anthelmintics for people with neurocysticercosis (Review)










Cochrane Database of Systematic Reviews
Notes Location: India
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Numbered in a random sequence using a random number table
Allocation concealment
(selection bias)
Low risk Quote: "Envelopes containing albendazole or placebo capsules for the full






Low risk Quote: "All persons involved in the study, i.e. patient, clinical investigator and
neuroradiologist were blind to this random allocation. Results were decoded
after completion of 6 months of study to identify the groups."
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "All persons involved in the study, i.e. patient, clinical investigator and
neuroradiologist were blind to this random allocation. Results were decoded








Low risk No evidence of selective reporting





Methods Type of study: randomized controlled trial
Duration: participants followed up for 24 months, recruited between February 2001 and February 2003
Participants Number: 178 enrolled, data available for 178 before exclusions/loss to follow-up (97 male, 77 female, 4
missing sex data)
Inclusion criteria: males and females of all ages, new onset symptoms associated with neurocysticerco-
sis for < 2 months, active and/or transitional neurocysticercosis cysts on axial CT or MRI of the brain
Exclusion criteria: only calcified cysts, pregnancy, papilloedema, active tuberculosis, syphilis, ocular
cysticercosis, active gastric ulcers, or any progressive or life-threatening disorder
Types of lesion: viable or non-viable cysts, or both
Position of lesions: intraparenchymal or extraparenchymal, or both
Number of lesions: ≥ 1
Interventions Group 1. Albendazole: 400 mg twice daily for 8 days (if ≥ 50 kg) or 15 mg/kg daily (if < 50 kg, including
children)
Carpio 2008 
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Group 2. Placebo: identical tablets for 8 days
All groups: prednisolone (all), antiepileptics (symptomatic only)
Outcomes Included in meta-analysis: seizure recurrence (24 months), death (any cause) (24 months), headache
(12, 24 months), signs of focal neurological deficit (12, 24 months), complete radiological clearance of
lesions (12 months), reduction of number of lesions (12 months), evolution of cysts (12 months)
Included in narrative only: frequency of seizures, frequency and nature of adverse events
Notes Location: Ecuador
Source of funding: NINDS grant R01-NS39403. Glaxo/SKB and Acromax Co supplied the active drug and
placebo.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were allocated to treatment group according to a stratified
block randomisation scheme. Two strata were considered: centre (sex centres)
and location of the cyst (parenchymal vs extraparenchymal). Permuted blocks




Low risk Quote: "The randomisation lists were kept in electronic form on a computer





Low risk Quote: "This paper reports the results of a double blind, randomised, placebo
controlled trial..."
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 178 participants randomized: 8 did not receive their allocation; 15 dropped out
of the trial after treatment; 161 (90%) included in the analysis (including 7 that
died before the end of follow-up).
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting





Methods Type of study: randomized controlled trial
Duration: participants followed up for 6 months, recruited between November 2007 and October 2008
Participants Number: 67 enrolled, data available for 67 with no exclusions/loss to follow-up (43 male, 24 female)
Inclusion criteria: males and females of all ages, new-onset seizures < 2 weeks, solitary contrast en-
hancing lesion on CT < 20 mm in diameter
Chaurasia 2010 
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Exclusion criteria: neurological deficit (other than minimal), evidence of raised intracranial pressure,
cerebral oedema on CT, already received anthelmintic or steroid, systemic disease (e.g. pulmonary tu-
berculosis, renal failure, or symptomatic secondary epilepsies)
Types of lesion: non-viable cyst
Position of lesions: intraparenchymal
Number of lesions: 1
Interventions Group 1. Albendazole: 15 mg/kg daily in 2 divided doses for 3 days
Group 2. Placebo: identical tablets for 3 days
All groups: antiepileptics (symptomatic only)
Outcomes Included in meta-analysis: seizure recurrence (6 months), complete radiological clearance of lesions (6
months), evolution of cysts (6 months)
Included in narrative only: frequency and nature of adverse events
Notes Location: India
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk Quote: "...we evaluated a 'three day course' of albendazole in a prospective
randomized double-blind trial."
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk 67 participants randomized: 67 (100%) included in the analysis.
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting





Methods Type of study: randomized controlled trial
Das 2007 
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Duration: participants followed up for 5 years; recruitment dates not described, but the trial was con-
ducted between January 1997 and January 2005
Participants Number: 300 enrolled, data available for 300 before exclusions/loss to follow-up (178 male, 122 female)
Inclusion criteria: males and females (age not stated but all recruited ≥ 18 years), recent-onset seizures,
residents of Burdwan District (West Bengal) in Eastern India, CT and MRI results with at least 2 lesions
strongly suggestive of neurocysticercosis with at least 1 in the vesicular stage, and antibodies against
cysticercosis detected by ELISA on at least 3 occasions
Exclusion criteria: history of primary seizure disorder, family history of seizure, pre-existing focal neuro-
logical deficit, any metabolic or hereditary disease
Types of lesion: unclear, though likely non-viable cysts with or without viable cysts
Position of lesions: mixed intra/extraparenchymal
Number of lesions: ≥ 2
Interventions Group 1. Albendazole 15 mg/kg daily plus dexamethasone 2 mg orally at 8-hour intervals for 14 days
(dexamethasone tapered "over time")
Group 2. Placebo: 14 days
All groups: antiepileptics (all)
Outcomes Included in meta-analysis: seizure recurrence (3 months), death (all cause) (12 months), hospital ad-
mission (all cause) (3 months), complete radiological clearance of lesions (12, 60 months)
Included in narrative only: headache, evolution of cysts
Notes Location: India
Source of funding: Burdwan Medical College and Hospital
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The patients were randomly allocated into two groups."
Allocation concealment
(selection bias)





Unclear risk Not described for participants, investigators, or medical staI, though placebo
used
Blinding of outcome as-
sessment (detection bias)
All outcomes









Low risk No evidence of selective reporting
Das 2007  (Continued)
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Methods Type of study: randomized controlled trial
Duration: participants followed up formally for 24 months, enrolled between May 2002 and October
2003, with telephone follow-up in October 2006
Participants Number: 123 enrolled, data available for 103 after exclusions/loss to follow-up (male/female data not
available)
Inclusion criteria: males and females of all ages, new-onset focal or generalized seizures, MRI-con-
firmed parenchymal solitary cysticercal lesion
Exclusion criteria: history of epilepsy, albendazole or praziquantel received previously, evidence of oth-
er lesions on CT/MRI, significant neurological deficits, raised intracranial pressure, seizures refractory to
acute treatment
Types of lesion: non-viable cyst
Position of lesions: intraparenchymal
Number of lesions: 1
Interventions Group 1. Albendazole 15 mg/kg daily in 2 divided doses for 28 days
Group 2. No albendazole
All groups: antiepileptics (all)
Outcomes Included in meta-analysis: complete radiological clearance of lesions (24 months)
Included in narrative only: seizure recurrence, time to seizure remission, evolution of cysts, radiological
resolution/development of oedema
Notes Location: India
Source of funding: Indian Council for Medical Research
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The patients were randomised to two groups by means of a random
number table consisting of 200 numbers..."
Allocation concealment
(selection bias)





High risk No placebo used, and no blinding described.
de Souza 2009 
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Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quotes: "The physicians who reviewed patient details at these follow-up vis-
its were blinded to the two treatment groups...", "...two independent trained
physicians who were blinded to treatment allocation analysed the MRIs." Note




Low risk 123 participants randomized: 20 lost to follow-up within the first 12 months,
103 (84%) included in the analysis.
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting





Methods Type of study: randomized controlled trial
Duration: participants followed up for 1 month, enrolled over a 2-year period, dates not stated
Participants Number: 163 enrolled, data available for 143 after exclusions but before loss to follow-up (65 male, 68
female)
Inclusion criteria: uncontrolled epilepsy probably due to neurocysticercosis, active/chronic forms of
neurocysticercosis after CT, without signs of raised intracranial pressure
Exclusion criteria: previous history of neurological disease apart from epilepsy, metabolic disorders,
cerebrovascular disease, meningoencephalitis, head injury, immunomodulatory agents received in the
previous 6 months, alternative cause for intracranial calcification, suspicion of tuberculoma/pyogenic
brain abscess/mycotic granuloma, primary or metastatic brain tumour, uncontrollable tonic-clonic
generalized motor seizures despite regular phenytoin 300 mg at night
Types of lesion: viable or non-viable cysts, or both
Position of lesions: not stated
Number of lesions: not stated
Interventions Group 1. Praziquantel 100 mg/kg daily in 4 divided doses for 1 day with prednisolone 40 mg daily for 5
days
Group 2. No praziquantel or prednisolone
All groups: phenytoin 400 mg once at night for 5 days (all)
Outcomes Included in meta-analysis: none
Included in narrative only: seizure recurrence, frequency of seizures
Notes Location: South Africa
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Foyaca-Sibat 2001 
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Random sequence genera-
tion (selection bias)
Low risk Quote: "...by block-randomization procedure."
Allocation concealment
(selection bias)





Low risk Quote: "The study was designed as a double blind, randomized trial..."
Blinding of outcome as-
sessment (detection bias)
All outcomes








Low risk No evidence of selective reporting





Methods Type of study: randomized controlled trial
Duration: participants followed up for 30 months, enrolled between January 1997 and March 1999
Participants Number: 120 enrolled, data available for 120 before exclusions/loss to follow-up (61 male, 59 female)
Inclusion criteria: adult patients, viable parenchymal cysts on CT, serological confirmation of Taenia
solium infection by ELISA, history of 1 or more spontaneous seizures within the previous 6 months but
less than 10 years in duration
Exclusion criteria: pregnancy, primary generalized seizures, > 20 cysts on CT, evidence of other diseases
not attributable to cysticercosis on CT, moderate or severe intracranial hypertension, status epilepti-
cus, focal neurological deficits, unstable vital signs, impending risk of death
Types of lesion: viable cysts
Position of lesions: intraparenchymal
Number of lesions: 1 to 20
Interventions Group 1. Albendazole 400 mg twice daily and dexamethasone 2 mg 3 times a day for 10 days
Group 2. Placebos: 2 placebos of similar appearance for 10 days
All groups: antiepileptics (all)
Outcomes Included in meta-analysis: seizure recurrence (30 months), complete radiological clearance of lesions
(6 months)
Garcia 2004 
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Included in narrative only: frequency of seizures, evolution of cysts, nature and frequency of adverse
events
Notes Location: Peru
Source of funding: US Food and Drug Administration (FD-R-001107-03) and the National Institute of Al-
lergy and Infectious Diseases, National Institutes of Health (U19-A145431) and the Tropical Medicine
Department of SmithKline Beecham
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Random assignment of the patients to one of the two study groups









Low risk Quote: "double-blind, placebo-controlled trial"
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 120 randomized: 4 did not receive allocated treatment, 2 excluded, 14 lost to




Low risk No evidence of selective reporting





Methods Type of study: randomized controlled trial
Duration: participants followed up for 6 months, enrolled between March 2000 and July 2000
Participants Number: 72 enrolled, data available for 72 with no exclusions/loss to follow-up (38 male, 34 female)
Inclusion criteria: children (age not stated, but all participants 1.5 to 12 years), ring-enhancing lesions
in brain parenchyma on CT, seizures without a history of epilepsy
Exclusion criteria: evidence of tuberculosis in the body, known epilepsy on antiepileptic prophylaxis,
chronic central nervous system disorders (e.g. congenital malformation, hydrocephalus, cerebral pal-
sy), neurodegenerative disorders, disc/nodular/calcific lesions on CT
Types of lesion: non-viable cysts
Position of lesions: intraparenchymal
Gogia 2003 
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Number of lesions: ≥ 1
Interventions Group 1. Albendazole 15 mg/kg daily in 2 divided doses for 28 days
Group 2. Placebo for 28 days
All groups: prednisolone 2 mg/kg daily for the 3 days preceding albendazole/placebo (all) and pheny-
toin 5 mg/kg daily (all)
Outcomes Included in meta-analysis: seizure recurrence (6 months), complete radiological clearance of lesions (6
months), evolution of cysts (6 months)
Included in narrative only: none
Notes Location: India
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










Low risk Quote: "The investigators and the patients were thus blinded to which drug
was being given to which patient. The radiologist responsible for reading the
X-rays was also blinded to the drug therapy."
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "The investigators and the patients were thus blinded to which drug
was being given to which patient. The radiologist responsible for reading the




Low risk 72 randomized: 72 (100%) included in analysis.
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting





Methods Type of study: randomized controlled trial
Duration: participants followed up for 6 months, enrolment dates not stated
Participants Number: 123 enrolled, data available for 123 before exclusions/loss to follow-up (65 male, 58 female)
Inclusion criteria: children aged 1 to 14 years, seizures plus 1 or 2 ring-enhancing lesions < 20 mm, ex-
cluding intraventricular cysts
Kalra 2003 
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Exclusion criteria: evidence of tuberculosis on chest radiograph, positive Mantoux test, history of con-
tact with a person with tuberculosis, intraocular or intraventricular cysts, disc or calcified lesions, mul-
tiple lesions (> 2), or hydrocephalus
Types of lesion: non-viable cysts
Position of lesions: intraparenchymal
Number of lesions: 1 to 2
Interventions Group 1. Albendazole 15 mg/kg daily for 28 days with dexamethasone 0.15 mg/kg for 5 days
Group 2. No dexamethasone or albendazole
All groups: antiepileptics (all)
Outcomes Included in meta-analysis: seizure recurrence (6 months), complete radiological clearance of lesions (6
months)
Included in narrative only: evolution of cysts, frequency and nature of adverse events
Notes Location: India
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "A simple randomization scheme was used for allocation of patients to
the treated or control groups."
Allocation concealment
(selection bias)
Low risk Quote: "Random assignment code was concealed up to the time of allocation





High risk Quotes: "...lack of blinding of the treating physician or patient...", "...open tri-
al..."
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Quotes: "...lack of blinding of the treating physician or patient...", "...open tri-









Low risk No evidence of selective reporting





Methods Type of study: randomized controlled trial
Khurana 2012 
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Duration: participants followed up for 6 months, enrolment dates not stated
Participants Number: 105 enrolled, data available for 105 with no exclusions/loss to follow-up (75 male, 30 female)
Inclusion criteria: all ages, new-onset seizures < 2 weeks, single enhancing lesions < 20 mm on CT
Exclusion criteria: evidence of raised intracranial pressure, neurological deficits, evidence of systemic
illness (e.g. tuberculosis, renal failure), abnormality on CT other than solitary cysticercus granuloma,
well-defined epileptic syndromes and symptomatic secondary epilepsies, prior albendazole treatment
Types of lesion: non-viable cyst
Position of lesions: intraparenchymal
Number of lesions: 1
Interventions Group 1. Albendazole 15 mg/kg daily for 3 days
Group 2. Albendazole 15 mg/kg daily for 15 days
Group 3. No albendazole
All groups: antiepileptics (all)
Outcomes Included in meta-analysis: seizure recurrence (6 months), complete radiological clearance of lesions (6
months), evolution of cysts (6 months)
Included in narrative only: frequency and nature of adverse events
Notes Location: India
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Included patients were randomly assigned to three groups of 35 each,
using a computer-generated table of random numbers."
Allocation concealment
(selection bias)





High risk No placebo used, and no blinding described ("open label randomized trial").
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 105 participants randomized: 105 (100%) included in the analysis.
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting
Other bias Low risk No evidence of other bias
Khurana 2012  (Continued)
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Methods Type of study: randomized controlled trial
Duration: participants followed up for 3 months, dates not stated
Participants Number: 75 enrolled, data available for 75 with no exclusions/loss to follow-up (52 male, 23 female)
Inclusion criteria: all ages, epilepsy, single small enhancing lesion on CT
Exclusion criteria: neurological deficit on examination
Types of lesion: non-viable
Position of lesions: intraparenchymal
Number of lesions: 1
Interventions Group 1. Albendazole 15 mg/kg daily for 7 days
Group 2. Placebo for 7 days
All groups: no additional management
Outcomes Included in meta-analysis: evolution of cysts (3 months)
Included in narrative only: none
Notes Location: India
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were randomly allocated to placebo or albendazole therapy."
Allocation concealment
(selection bias)





Low risk Quote: "...we carried out a doubleblind, randomized, placebo-controlled
study..."
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quotes: "CTs were assessed by a neuroradiologist (N.K.M.) who was not aware





Low risk 75 participants randomized: 75 (100%) included in the analysis.
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting
Padma 1994 
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Methods Type of study: randomized controlled trial
Duration: participants followed up for 3 months, dates not stated
Participants Number: 29 enrolled, data available for 29 with no exclusions/loss to follow-up (22 male, 7 female)
Inclusion criteria: all ages, multiple cystic lesions suggestive of cysticercosis on CT
Exclusion criteria: calcified lesions only
Types of lesion: viable or non-viable cysts, or both
Position of lesions: not stated, presumed mixed intra/extraparenchymal
Number of lesions: ≥ 2
Interventions Group 1. Albendazole 15 mg/kg per day in 2 divided doses for 7 days
Group 2. Placebo: tablets similar in appearance for 7 days
All groups: antiepileptics (participants with history of seizures)
Outcomes Included in meta-analysis: reduction of number of lesions (3 months), radiological resolution/develop-
ment of oedema (3 months)
Included in narrative only: none
Notes Location: India
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk Quotes: "...double-blind, placebo-controlled study...", "Placebo tablets of sim-
ilar appearance...", "The CT scans were assessed...by a neuroradiologist who
was not aware of the treatment given."
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quotes: "...double-blind, placebo-controlled study...", "Placebo tablets of sim-
ilar appearance...", "The CT scans were assessed...by a neuroradiologist who
was not aware of the treatment given."
Incomplete outcome data
(attrition bias)
Low risk 29 randomized: 29 (100%) included in the analysis.
Padma 1995 
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Low risk No evidence of selective reporting





Methods Type of study: randomized controlled trial
Duration: participants followed up for 3 to 6 months, recruited 1994 to 1998
Participants Number: 380 participants likely enrolled (description is not clear), data available for 176 after exclu-
sions/loss to follow-up (of original 500 patient population: 272 male, 228 female)
Inclusion criteria: children aged up to 14 years, a single small ring-enhancing lesion in brain parenchy-
ma on CT/MRI
Exclusion criteria: none stated
Types of lesion: non-viable cyst
Position of lesions: intraparenchymal
Number of lesions: 1
Interventions Group 1. Albendazole 15 mg/kg daily for 28 days (addition of prednisolone unclear)
Group 2. No albendazole
All groups: antiepileptics (participants with seizures)
Outcomes Included in meta-analysis: complete radiological clearance of lesions (3 to 6 months)
Included in narrative only: evolution of cysts
Notes Location: India
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quotes: "Children...were chosen at random to receive either albendazole









High risk No placebo used, and no blinding described.
Singhi 2000 
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Blinding of outcome as-
sessment (detection bias)
All outcomes








Low risk No evidence of selective reporting





Methods Type of study: randomized controlled trial
Duration: participants followed up for 18 months, recruitment dates not stated
Participants Number: 133 participants enrolled, data available for 110 after exclusions/loss to follow-up (66 male, 44
female)
Inclusion criteria: children aged up to 14 years, seizure history < 3 months duration, a single small en-
hancing lesion on CT/MRI
Exclusion criteria: neurological deficit
Types of lesion: non-viable cyst
Position of lesions: intraparenchymal
Number of lesions: 1
Interventions Group 1. Albendazole 15 mg/kg daily for 28 days
Group 2: Albendazole 15 mg/kg daily for 28 days plus prednisolone
Group 2. No albendazole plus prednisolone
All groups: antiepileptics (all)
Outcomes Included in meta-analysis: seizure recurrence (72 weeks), complete radiological clearance of lesions (6
months)
Included in narrative only: seizure recurrence after withdrawal of antiepileptics
Notes Location: India
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The children were randomly assigned...using random number tables."
Singhi 2004 
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Allocation concealment
(selection bias)





High risk No placebo used, and no blinding described.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "All CT scans were assessed by a neuroradiologist (N.K.), who was




Unclear risk 133 participants randomized: 23 lost to follow-up (study arm not described),
110 (83%) included in the analysis.
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting





Methods Type of study: randomized controlled trial
Duration: participants were followed up for 3 to 4 months, dates not stated
Participants Number: 25 enrolled, data available for 25 with no exclusions/loss to follow-up (16 male, 9 female)
Inclusion criteria: adults, parenchymal brain cysticercosis
Exclusion criteria: none stated
Types of lesion: viable cysts
Postition of lesions: intraparenchymal
Number of lesions: ≥ 1
Interventions Group 1. Albendazole 15 mg/kg daily for 1 month
Group 2. Praziquantel 50 mg/kg daily for 14 days
Group 3. No albendazole or praziquantel
All groups: antiepileptics (participants already receiving antiepileptics)
Outcomes Included in meta-analysis: complete radiological clearance of lesions (3 to 4 months), reduction of
number of lesions (3 to 4 months)
Included in narrative only: frequency and nature of adverse events
Notes Location: Mexico
Source of funding: partially supported by Subsecretaría de Regulación Sanitaria y Desarrollo, Secre-
taria de Salud de México, México City
Sotelo 1988 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were randomly allocated in three groups..."
Allocation concealment
(selection bias)





High risk No placebo used, and no blinding described.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 25 participants enrolled; 25 (100%) included in the analysis.
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting
Other bias Low risk No evidence of other bias
Sotelo 1988  (Continued)
CT: computed tomography
ELISA: enzyme-linked immunosorbent assay
MRI: magnetic resonance imaging
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Alarcon 1989 Not a randomized controlled trial for intervention arms versus control: outcome of control arm de-
termined from comparisons between a CT scan at the beginning of the trial and images taken years
before. This trial was included in previous versions of this review.
Botero 1993 No control: albendazole treatment arm only
Bustos 2006 No control: albendazole treatment arm only
Carpio 1995 Quasi-randomized trial: 1 assignment sequence used
Chen 1984 Article unavailable: full-text of all articles referencing this trial were accessed, and it does not ap-
pear to be relevant to this version of the review
Cruz 1995 No supportive treatment control: 3 albendazole durations compared. This trial was included in pre-
vious versions of this review.
Del Brutto 1997 No control: albendazole treatment arm only.
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Study Reason for exclusion
Del Brutto 1999 No supportive treatment control: albendazole and praziquantel compared. This trial was included
in previous versions of this review.
Escobedo 1987 No control: albendazole treatment arm only
Foyaca-Sibat 2016 No comparison of interest: praziquantel, prednisone, and sodium valproate compared to sodium
valproate alone
Garcia 1997 No supportive treatment control: 2 albendazole durations compared. This trial was included in pre-
vious versions of this review.
Gongora-Rivera 2006 No supportive treatment control: 2 albendazole doses compared. This trial was included in previ-
ous versions of this review.
Kaur 2009 No supportive treatment control: albendazole plus praziquantel compared to albendazole plus
placebo. This trial was included in previous versions of this review.
Ma 1984 Article unavailable: full-text of all articles referencing this trial were accessed, and it does not ap-
pear to be relevant to this version of the review
Pretell 2000 Likely a quasi-randomized trial: patients were "openly assigned" with "initial group" receiving
praziquantel and "remaining patients" not receiving praziquantel. Authors contacted for clarifica-
tion without reply.
Singhi 2003 No supportive treatment control: 2 albendazole durations compared. This trial was included in pre-
vious versions of this review.
Sotelo 1990 No supportive treatment control: 2 albendazole durations compared to 2 praziquantel durations.
This trial was included in previous versions of this review.




D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Albendazole versus placebo or no anthelmintic
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.1 Seizure recurrence 10 1054 Risk Ratio (M-H, Fixed, 95%
CI)
0.94 [0.78, 1.14]
1.2 Seizure recurrence subgroup
analysis: number of cysts
6   Risk Ratio (M-H, Fixed, 95%
CI)
Subtotals only
1.2.1 Participants with a single lesion 5 396 Risk Ratio (M-H, Fixed, 95%
CI)
0.61 [0.40, 0.91]
1.2.2 Participants with multiple (> 1)
lesions
2 321 Risk Ratio (M-H, Fixed, 95%
CI)
2.05 [1.28, 3.31]
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Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.3 Seizure recurrence subgroup
analysis: viability of cysts
8   Risk Ratio (M-H, Fixed, 95%
CI)
Subtotals only
1.3.1 Participants with viable cysts 2 174 Risk Ratio (M-H, Fixed, 95%
CI)
0.91 [0.62, 1.33]
1.3.2 Participants with non-viable
cysts
6 507 Risk Ratio (M-H, Fixed, 95%
CI)
0.55 [0.38, 0.78]
1.4 Seizure recurrence subgroup
analysis: position of cysts
8   Risk Ratio (M-H, Fixed, 95%
CI)
Subtotals only
1.4.1 Participants with intraparenchy-
mal cysts
8 681 Risk Ratio (M-H, Fixed, 95%
CI)
0.66 [0.51, 0.86]
1.5 Seizure recurrence subgroup
analysis: age of participants
6   Risk Ratio (M-H, Fixed, 95%
CI)
Subtotals only
1.5.1 Children (under 16 years old) 4 335 Risk Ratio (M-H, Fixed, 95%
CI)
0.46 [0.30, 0.69]
1.5.2 Adults (16 years old or older) 2 416 Risk Ratio (M-H, Fixed, 95%
CI)
1.45 [1.06, 1.98]
1.6 Seizure recurrence subgroup
analysis: corticosteroid use
6   Risk Ratio (M-H, Fixed, 95%
CI)
Subtotals only
1.6.1 Participants receiving corticos-
teroids
3 208 Risk Ratio (M-H, Fixed, 95%
CI)
0.83 [0.61, 1.13]
1.6.2 Participants not receiving corti-
costeroids
3 230 Risk Ratio (M-H, Fixed, 95%
CI)
0.97 [0.50, 1.88]
1.7 Death (any cause) 2 470 Risk Ratio (M-H, Fixed, 95%
CI)
0.83 [0.24, 2.85]
1.8 Hospital admission (any cause) 1 300 Risk Ratio (M-H, Fixed, 95%
CI)
2.50 [1.52, 4.11]
1.9 Headache 1 161 Risk Ratio (M-H, Fixed, 95%
CI)
0.98 [0.91, 1.06]
1.10 Signs of focal neurological deficit 1 161 Risk Ratio (M-H, Fixed, 95%
CI)
0.89 [0.65, 1.23]
1.11 Surgical intervention 1 83 Risk Ratio (M-H, Fixed, 95%
CI)
1.64 [0.07, 38.94]
1.12 Complete radiological clearance
of lesions
13 1324 Risk Ratio (M-H, Fixed, 95%
CI)
1.22 [1.07, 1.39]
1.13 Reduction of number of lesions 3 115 Risk Ratio (M-H, Fixed, 95%
CI)
1.33 [0.89, 1.98]
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Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.14 Evolution of cysts 6 434 Risk Ratio (M-H, Fixed, 95%
CI)
1.27 [1.10, 1.47]
1.15 Radiological resolution of oede-
ma
1 29 Risk Ratio (M-H, Fixed, 95%
CI)
0.89 [0.61, 1.28]
1.16 Radiological development of
oedema
1 29 Risk Ratio (M-H, Fixed, 95%
CI)
0.81 [0.06, 11.77]
1.17 Complete radiological clearance
of lesions subgroup analysis: viability
of cysts
11   Risk Ratio (M-H, Fixed, 95%
CI)
Subtotals only
1.17.1 Participants with viable cysts 3 207 Risk Ratio (M-H, Fixed, 95%
CI)
2.52 [1.65, 3.85]
1.17.2 Participants with non-viable
cysts



















Heterogeneity: Chi² = 26.99, df = 9 (P = 0.001); I² = 67%
Test for overall effect: Z = 0.61 (P = 0.54)
































































M-H, Fixed, 95% CI
1.05 [0.21 , 5.26]
0.66 [0.29 , 1.47]
1.00 [0.74 , 1.35]
3.09 [0.34 , 28.23]
2.33 [1.41 , 3.86]
0.89 [0.60 , 1.32]
0.56 [0.19 , 1.64]
0.40 [0.17 , 0.94]
0.75 [0.34 , 1.66]
0.34 [0.16 , 0.71]
0.94 [0.78 , 1.14]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours albendazole Favours no anthelmintic
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Analysis 1.2.   Comparison 1: Albendazole versus placebo or no anthelmintic,
Outcome 2: Seizure recurrence subgroup analysis: number of cysts
Study or Subgroup








Heterogeneity: Chi² = 4.78, df = 4 (P = 0.31); I² = 16%
Test for overall effect: Z = 2.42 (P = 0.02)





Heterogeneity: Chi² = 2.75, df = 1 (P = 0.10); I² = 64%
Test for overall effect: Z = 2.96 (P = 0.003)






















































M-H, Fixed, 95% CI
0.66 [0.29 , 1.47]
3.09 [0.34 , 28.23]
0.68 [0.18 , 2.53]
0.75 [0.34 , 1.66]
0.34 [0.16 , 0.71]
0.61 [0.40 , 0.91]
2.33 [1.41 , 3.86]
0.41 [0.05 , 3.02]
2.05 [1.28 , 3.31]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours albendazole Favours no anthelmintic
 
 
Analysis 1.3.   Comparison 1: Albendazole versus placebo or no anthelmintic,
Outcome 3: Seizure recurrence subgroup analysis: viability of cysts
Study or Subgroup





Heterogeneity: Chi² = 0.04, df = 1 (P = 0.84); I² = 0%
Test for overall effect: Z = 0.50 (P = 0.61)









Heterogeneity: Chi² = 5.27, df = 5 (P = 0.38); I² = 5%



























































M-H, Fixed, 95% CI
1.05 [0.21 , 5.26]
0.89 [0.60 , 1.32]
0.91 [0.62 , 1.33]
0.66 [0.29 , 1.47]
3.09 [0.34 , 28.23]
0.56 [0.19 , 1.64]
0.40 [0.17 , 0.94]
0.75 [0.34 , 1.66]
0.34 [0.16 , 0.71]
0.55 [0.38 , 0.78]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours albendazole Favours no anthelmintic
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Analysis 1.4.   Comparison 1: Albendazole versus placebo or no anthelmintic,
Outcome 4: Seizure recurrence subgroup analysis: position of cysts
Study or Subgroup











Heterogeneity: Chi² = 9.08, df = 7 (P = 0.25); I² = 23%






















































M-H, Fixed, 95% CI
1.05 [0.21 , 5.26]
0.66 [0.29 , 1.47]
3.09 [0.34 , 28.23]
0.89 [0.60 , 1.32]
0.56 [0.19 , 1.64]
0.40 [0.17 , 0.94]
0.75 [0.34 , 1.66]
0.34 [0.16 , 0.71]
0.66 [0.51 , 0.86]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours albendazole Favours no anthelmintic
 
 
Analysis 1.5.   Comparison 1: Albendazole versus placebo or no anthelmintic,
Outcome 5: Seizure recurrence subgroup analysis: age of participants
Study or Subgroup







Heterogeneity: Chi² = 1.62, df = 3 (P = 0.66); I² = 0%
Test for overall effect: Z = 3.66 (P = 0.0003)





Heterogeneity: Chi² = 9.32, df = 1 (P = 0.002); I² = 89%

















































M-H, Fixed, 95% CI
0.66 [0.29 , 1.47]
0.56 [0.19 , 1.64]
0.40 [0.17 , 0.94]
0.34 [0.16 , 0.71]
0.46 [0.30 , 0.69]
2.33 [1.41 , 3.86]
0.89 [0.60 , 1.32]
1.45 [1.06 , 1.98]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours albendazole Favours no anthelmintic
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Analysis 1.6.   Comparison 1: Albendazole versus placebo or no anthelmintic,
Outcome 6: Seizure recurrence subgroup analysis: corticosteroid use
Study or Subgroup






Heterogeneity: Chi² = 2.20, df = 2 (P = 0.33); I² = 9%
Test for overall effect: Z = 1.18 (P = 0.24)






Heterogeneity: Chi² = 1.46, df = 2 (P = 0.48); I² = 0%

















































M-H, Fixed, 95% CI
0.66 [0.29 , 1.47]
1.00 [0.74 , 1.35]
0.56 [0.19 , 1.64]
0.83 [0.61 , 1.13]
1.05 [0.21 , 5.26]
3.09 [0.34 , 28.23]
0.75 [0.34 , 1.66]
0.97 [0.50 , 1.88]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours albendazole Favours no anthelminic
 
 






Heterogeneity: Chi² = 2.09, df = 1 (P = 0.15); I² = 52%
Test for overall effect: Z = 0.29 (P = 0.77)
























M-H, Fixed, 95% CI
0.41 [0.08 , 2.05]
5.00 [0.24 , 103.28]
0.83 [0.24 , 2.85]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours albendazole Favours no anthelmintic
 
 
Analysis 1.8.   Comparison 1: Albendazole versus placebo or






Test for overall effect: Z = 3.61 (P = 0.0003)



















M-H, Fixed, 95% CI
2.50 [1.52 , 4.11]
2.50 [1.52 , 4.11]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours albendazole Favours no anthelmintic
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Test for overall effect: Z = 0.40 (P = 0.69)



















M-H, Fixed, 95% CI
0.98 [0.91 , 1.06]
0.98 [0.91 , 1.06]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours albendazole Favours no anthelmintic
 
 
Analysis 1.10.   Comparison 1: Albendazole versus placebo or






Test for overall effect: Z = 0.71 (P = 0.47)



















M-H, Fixed, 95% CI
0.89 [0.65 , 1.23]
0.89 [0.65 , 1.23]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours albendazole Favours no anthelmintic
 
 






Test for overall effect: Z = 0.30 (P = 0.76)



















M-H, Fixed, 95% CI
1.64 [0.07 , 38.94]
1.64 [0.07 , 38.94]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours albendazole Favours no anthelmintic
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Analysis 1.12.   Comparison 1: Albendazole versus placebo or no

















Heterogeneity: Chi² = 39.54, df = 12 (P < 0.0001); I² = 70%
Test for overall effect: Z = 2.98 (P = 0.003)















































































M-H, Fixed, 95% CI
2.26 [1.34 , 3.80]
1.72 [1.02 , 2.89]
1.15 [0.52 , 2.56]
2.06 [1.34 , 3.16]
0.65 [0.43 , 0.96]
1.16 [0.79 , 1.70]
2.58 [1.25 , 5.31]
0.98 [0.60 , 1.61]
1.52 [0.73 , 3.17]
1.65 [1.03 , 2.64]
0.72 [0.45 , 1.16]
0.98 [0.79 , 1.23]
7.09 [0.48 , 105.40]
1.22 [1.07 , 1.39]
Risk Ratio
M-H, Fixed, 95% CI
0.2 0.5 1 2 5
Favours no anthelmintic Favours albendazole
 
 
Analysis 1.13.   Comparison 1: Albendazole versus placebo or







Heterogeneity: Chi² = 3.61, df = 2 (P = 0.16); I² = 45%
Test for overall effect: Z = 1.38 (P = 0.17)





























M-H, Fixed, 95% CI
1.15 [0.71 , 1.87]
0.93 [0.46 , 1.87]
10.36 [0.72 , 148.78]
1.33 [0.89 , 1.98]
Risk Ratio
M-H, Fixed, 95% CI
0.001 0.1 1 10 1000
Favours no anthelmintic Favours albendazole
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Heterogeneity: Chi² = 4.10, df = 5 (P = 0.53); I² = 0%
Test for overall effect: Z = 3.18 (P = 0.001)












































M-H, Fixed, 95% CI
1.58 [1.04 , 2.42]
1.20 [0.91 , 1.57]
1.52 [1.15 , 2.01]
1.14 [0.81 , 1.63]
1.18 [0.84 , 1.64]
0.88 [0.37 , 2.09]
1.27 [1.10 , 1.47]
Risk Ratio
M-H, Fixed, 95% CI
0.5 0.7 1 1.5 2
Favours no anthelmintic Favours albendazole
 
 
Analysis 1.15.   Comparison 1: Albendazole versus placebo or no






Test for overall effect: Z = 0.65 (P = 0.52)



















M-H, Fixed, 95% CI
0.89 [0.61 , 1.28]
0.89 [0.61 , 1.28]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours no anthelmintic Favours albendazole
 
 
Analysis 1.16.   Comparison 1: Albendazole versus placebo or no






Test for overall effect: Z = 0.15 (P = 0.88)



















M-H, Fixed, 95% CI
0.81 [0.06 , 11.77]
0.81 [0.06 , 11.77]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours albendazole Favours no anthelmintic
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Analysis 1.17.   Comparison 1: Albendazole versus placebo or no anthelmintic, Outcome
17: Complete radiological clearance of lesions subgroup analysis: viability of cysts
Study or Subgroup






Heterogeneity: Chi² = 0.74, df = 2 (P = 0.69); I² = 0%
Test for overall effect: Z = 4.28 (P < 0.0001)











Heterogeneity: Chi² = 18.60, df = 7 (P = 0.010); I² = 62%










































































M-H, Fixed, 95% CI
2.26 [1.34 , 3.80]
2.58 [1.25 , 5.31]
7.09 [0.48 , 105.40]
2.52 [1.65 , 3.85]
1.72 [1.02 , 2.89]
2.06 [1.34 , 3.16]
1.16 [0.79 , 1.70]
0.98 [0.60 , 1.61]
1.52 [0.73 , 3.17]
1.65 [1.03 , 2.64]
0.72 [0.45 , 1.16]
0.98 [0.79 , 1.23]
1.22 [1.05 , 1.41]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours albendazole Favours no anthelmintic
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A D D I T I O N A L   T A B L E S

















Tertiary All Intraparenchymal 1 to 6 Viable CT Albendazole No
Baranwal
1998





Tertiary All Intraparenchymal and ex-
traparenchymal








Tertiary All Intraparenchymal 1 Non-viable CT Albendazole No



















































Tertiary ≤ 12 years Intraparenchymal ≥ 1 Non-viable CT Albendazole Yes










































































































































































India Not stated Tertiary All Intraparenchymal 1 Non-viable CT Albendazole Not stated
Padma
1995
India Not stated Tertiary All Intraparenchymal and ex-
traparenchymal
≥ 2 Viable or
non-viable,
or both










India Not stated Tertiary 1 to 14 years Intraparenchymal 1 Non-viable CT Albendazole Yes
Sotelo
1988








Table 1.   Summary of characteristics of included studies  (Continued)
CT: computed tomography
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Trial ID Anthelmintic Dose regimen Control arm Steroid Antiepileptic
Alarcon 2001 Albendazole Group 1: 15 mg/kg dai-
ly for 3 days
Group 2: 15 mg/kg dai-
ly for 8 days
Group 3: no al-
bendazole
None Participants with seizures:
various (including pheny-




Albendazole Group 1: 15 mg/kg dai-







prednisolone 1 to 2
mg/kg/day for 5 days
Participants with seizures:
carbamazepine (phenytoin
if carbamazepine was unaf-
fordable to participant's fam-
ily)
Carpio 2008 Albendazole Group 1: 400 mg twice
daily for 8 days (if ≥ 50
kg) or 15 mg/kg daily







daily for 8 days, fol-
lowed by 50 mg daily
for 1 week, followed
by 25 mg daily for 1
week (if ≥ 50 kg) or
1.5 mg/kg/day for
8 days, followed by
1.0 mg/kg/day for 1
week, followed by
0.5 mg/kg/day for 1
week (if < 50 kg)
Participants with seizures:
phenytoin (carbamazepine
if phenytoin is contraindi-




Albendazole Group 1: 15 mg/kg dai-





None All participants: phenytoin,
carbamazepine, or oxcar-
bazepine as monotherapy
Das 2007 Albendazole Group 1: 15 mg/kg day




Group 1 only: dexam-
ethasone 2 mg oral-
ly 3 times a day for





de Souza 2009 Albendazole Group 1: 15 mg/kg dai-
ly in 2 divided doses
for 28 days
Group 2: no al-
bendazole
None All participants: carba-
mazepine, oxcarbazepine,
phenytoin, or phenobarbi-




Praziquantel Group 1: 100 mg/kg
daily in 4 divided dos-
es for 1 day
Group 2: no
praziquantel
Group 1 only: pred-
nisone 40 mg daily
for 5 days
All participants: 400 mg
phenytoin at night
Garcia 2004 Albendazole Group 1: 400 mg twice
daily for 10 days
Group 2: 2
placebos
Group 1 only: dexam-
ethasone 2 mg orally
3 times a day for 10
days
All participants: monother-
apy as per the participant's
attending neurologist, or
phenytoin if not already re-
ceiving treatment
Gogia 2003 Albendazole Group 1: 15 mg/kg dai-






kg/day for 3 days
All participants: phenytoin 5
mg/kg daily
Table 2.   Anthelmintic dose regimens and supportive care used in included studies 
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Kalra 2003 Albendazole Group 1: 15 mg/kg dai-
ly for 28 days
Group 2:no al-
bendazole
Group 1 only: dexam-
ethasone 0.15 mg/kg
in 2 to 3 divided dos-
es for 5 days
All participants: monother-
apy as per the participant's
attending neurologist, or
phenytoin if not already re-
ceiving treatment
Khurana 2012 Albendazole Group 1: 15 mg/kg dai-
ly in 2 divided doses
for 3 days
Group 2: 15 mg/kg dai-
ly in 2 divided doses
for 15 days
Group 3: no al-
bendazole
None All participants: oxcar-
bazepine
Padma 1994 Albendazole Group 1: 15 mg/kg dai-
ly for 7 days
Group 2:
placebo
Not stated Not stated
Padma 1995 Albendazole Group 1: 15 mg/kg dai-





Not stated Participants with seizure his-
tory: antiepileptic medica-
tion "continued"
Singhi 2000 Albendazole Group 1: 15 mg/kg dai-
ly for 28 days









Singhi 2004 Albendazole Group 1: 15 mg/kg dai-
ly for 28 days
Group 2: 15 mg/kg









daily for 5 days
Group 3: pred-
nisolone 2 mg/kg







15 mg/kg daily for 1
month
Group 2: praziquantel
50 mg/kg daily for 14
days










tic medication continued for
those receiving it
Table 2.   Anthelmintic dose regimens and supportive care used in included studies  (Continued)
 
 
Trial ID Short-term follow-up points Long-term follow-up points
Alarcon 2001 3 months
12 months
≥ 24 months
Baranwal 1998 1 month
3 months
15 months
Carpio 2008 2 weeks
1, 2, 3, 4, 5, 6 months
15 months
18 months
Table 3.   Follow-up duration of included studies 
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Chaurasia 2010 6 months -
Das 2007 1, 2, 3, 4, 5, 6 months
9 months
12 months
Every 3 months between 15 and 60
months




Telephone follow-up October 2006
(Follow-up mean of 31.4 months, +/-
14.8 months)
Foyaca-Sibat 2001 1 month -










Gogia 2003 6 months -




Khurana 2012 1, 2, 3, 4, 5, 6 months -




Padma 1995 1 month
3 months
-
Singhi 2000 Between 3 and 6 months (mean 3.5) -






Table 3.   Follow-up duration of included studies  (Continued)
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Sotelo 1988 3 months (Groups 1 and 2: intervention)
4 months (Group 3: control)
-
Table 3.   Follow-up duration of included studies  (Continued)
 
 
Trial ID Seizure status Additional
health status in-
dicators
Radiological findings Adverse events
Alarcon 2001 Seizure recurrence Surgical inter-
vention
Complete radiological clearance of lesions Frequency and
nature of ad-
verse events*













Complete radiological clearance of lesions














Complete radiological clearance of lesions
Evolution of cysts*
-
de Souza 2009 Seizure recurrence*
Time to seizure re-
mission*
- Complete radiological clearance of lesions
Evolution of cysts*









Garcia 2004 Seizure recurrence
Frequency of
seizures*





Gogia 2003 Seizure recurrence - Complete radiological clearance of lesions
Evolution of cysts
-
Table 4.   Output measures of interest of included studies 
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Padma 1994 - - Evolution of cysts -
Padma 1995 - - Reduction of number of lesions
Radiological resolution/development of oedema
-
Singhi 2000 - - Complete radiological clearance of lesions
Evolution of cysts*
-




- Complete radiological clearance of lesions -
Sotelo 1988 - - Complete radiological clearance of lesions




Table 4.   Output measures of interest of included studies  (Continued)
*Results not suitable for meta-analysis, but included in the narrative of results.
 
 
A P P E N D I C E S
Appendix 1. Search methods: detailed search strategies
 
  Cochrane Central Register of Controlled Trials
Issue 10 of 12, October 2020
1 'MeSH descriptor: [Taenia solium] explode all trees'
2 (Taenia solium):ti, ab, kw
3 Neurocysticercosis:ti, ab,kw
4 'MeSH descriptor: [Neurocysticercosis] explode all trees'
5 "brain and cysticercosis"
6 cerebral cysticercosis
7 #1 or #2 or #3 or #4 or #5 or #6
8 Albendazole:ti, ab, kw
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9 Praziquantel:ti, ab, kw
10 'MeSH descriptor: [albendazole] explode all trees'
11 'MeSH descriptor: [praziquantel] explode all trees'
12 'MeSH descriptor: [Anticestodal agents] explode all trees'
13 antihelminthic* OR anti-helminthic* OR anthelmintic*:ti, ab, kw
14 #8 or #9 or #10 or #11 or #12 or #13






#3 Search taenia solium Field: Title/Abstract
#5 Search "Taenia solium"[Mesh] Field: Title/Abstract
#6 Search "Neurocysticercosis"[Mesh] Field: Title/Abstract
#7 Search neurocysticerc* Field: Title/Abstract
#8 Search "brain cysticerc*" or "cerebral cysticerc*" Field: Title/Abstract
#9 Search ((((#8) OR #7) OR #6) OR #5) OR #3 Field: Title/Abstract
#10 Search albendazole Field: Title/Abstract
#12 Search "Albendazole"[Mesh] Field: Title/Abstract
#13 Search praziquantel Field: Title/Abstract
#16 Search "Praziquantel"[Mesh] Field: Title/Abstract
#17 Search "Anticestodal Agents"[Mesh] Field: Title/Abstract
#18 Search antihelminthic* OR anti-helminthic* OR anthelmintic* Field: Title/Abstract
#19 Search (((((#18) OR #17) OR #16) OR #13) OR #12) OR #10 Field: Title/Abstract
#20 Search (#19) AND #9 Field: Title/Abstract
#22 Search "Randomized Controlled Trial" [Publication Type] OR "Controlled Clinical Trial" [Publica-
tion Type] Field: Title/Abstract
#23 Search randomized or placebo Field: Title/Abstract
#25 Search randomly or trial or groups Field: Title/Abstract
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#28 Search "drug therapy" [Subheading] Field: Title/Abstract
#29 Search (((#28) OR #25) OR #23) OR #22 Field: Title/Abstract
#30 Search (animals[MeSH Terms]) NOT humans[MeSH Terms] Field: Title/Abstract
#31 Search (#29) NOT #30 Field: Title/Abstract
#32 Search (#31) AND #20 Field: Title/Abstract
#33 Search (#31) AND #20 Filters: Humans; Field: Title/Abstract
  (Continued)
 
Database: Embase 1947-Present, updated daily
Search Strategy:
--------------------------------------------------------------------------------
1 taenia solium.mp. or Taenia solium/
2 neurocysticercosis/
3 neurocysticerc*.mp.
4 ("brain cysticerc*" or "cerebral cysticerc*").mp.
5 1 or 2 or 3 or 4
6 albendazole.mp. or albendazole/
7 praziquantel.mp. or praziquantel/
8 anthelmintic agent/ or anthelminths.mp.
9 (antihelminthic* or anti-helminthic* or anthelmintic*).mp.
10 6 or 7 or 8 or 9
11 5 and 10
12 randomized controlled trial/ or controlled clinical trial/
13 (randomized or randomised or placebo or double-blind* or single-blind*).ti. or (randomized or randomised or placebo or double-blind*
or single-blind*).ab.
14 12 or 13
15 11 and 14
LILACS
tw:(neurocysticercosis) AND ( db:("LILACS") AND type_of_study:("clinical_trials"))
Clinicaltrials.gov:
Neurocysticercosis , Taeniasis, Cysticercosis
WHO ICTRP: Neurocysticerc*
Appendix 2. Prespecified changes for review update 2021
 
Anthelmintics for people with neurocysticercosis (Review)










Cochrane Database of Systematic Reviews
Protocol section Revised protocol
Background and research
question
• We reworded and reordered the Background for a more logical flow and to discuss types of cyst/
lesion in more depth.
• We added a paragraph to the Background discussing the life cycle of Taenia solium.
• Inclusion of references to support new imaging diagnostic criteria, Del Brutto 2017, and new de-
velopments in treatment recommendations (White 2018).
Inclusion criteria • We adjusted the definition of the comparison to only include supportive treatment with or with-
out corticosteroids. Previous versions of this review compared different anthelmintic regimens in
addition to supportive treatment comparisons. We believe this resulted in a more focused review.
• We adjusted the primary outcomes: definition of remission, time to seizure remission, and group-
ings for seizure frequency.
• We amended the secondary outcomes: neurological symptoms divided into headache and focal
deficit, and additional imaging outcomes to reflect new developments in imaging.
• The usual standards of care are still covered by old inclusion criteria.
• No standardized core outcomes available.
• Previous version included only randomized controlled trials; the same criterion is suitable.
Methods • We incorporated GRADE into this update, which was not included in previous versions of the re-
view.
• We included a ‘Summary of findings’ table.
• We included an extra element of stratification (intraparenchymal/extraparenchymal) in this re-
view update due to the difference in nature of prognosis and the contribution of oedema/raised
intracranial pressure to mortality.
• We performed subanalysis in the same manner as previous versions of the review.
• The overall structure of this review is the same as previous versions.
This table was approved by the Cochrane Infectious Diseases Group editorial team on 14 September 2018.
 
 
W H A T ' S   N E W
 
Date Event Description
27 May 2021 New citation required and conclusions
have changed
This review updates the Cochrane Review 'Anthelmintics for peo-
ple with neurocysticercosis' (Abba 2010). A new team of authors
worked on this review update. The criteria for inclusion of trials
has changed.
27 May 2021 New search has been performed The review author team revised the protocol, including updat-
ed definitions within the Methods (intervention/outcomes). This
was approved by the Cochrane Infectious Diseases Group editori-
al team on 16 March 2018 (see Appendix 2).
 
H I S T O R Y
Protocol first published: Issue 4, 2006
Review first published: Issue 2, 1996
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Date Event Description
15 February 2010 Amended Corrected search dates in abstract
1 September 2009 New citation required and conclusions
have changed
This review replaced an earlier Cochrane Review 'Drugs for treat-
ing neurocysticercosis (tapeworm infection of the brain)' (Salinas
1999), which was withdrawn from the Cochrane Library in 2005
due to the availability of new trial evidence.
A new team of authors worked on this review. The criteria for in-
clusion of trials has changed.
5 May 2009 New search has been performed Search updated.
 
C O N T R I B U T I O N S   O F   A U T H O R S
The selection of studies for inclusion, assessment of methodological quality, and data extraction were undertaken as indicated in the
Methods section of the review by EJMM, KA, and LNR. EJMM undertook the analyses, in consultation with KA and LNR. All three review
authors contributed to the Discussion and Authors' conclusions section of the review. All review authors read and approved the final review
update version.
D E C L A R A T I O N S   O F   I N T E R E S T
Edward JM Monk: none known.
Katharine Abba: none known.
Lakshmi N Ranganathan: none known.
S O U R C E S   O F   S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK
• Apollo Hospital, Chennai, India
External sources
• Foreign, Commonwealth and Development OIice (FCDO), UK
Project number 300342-104
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We added an additional analysis stratification: single and multiple (> 1) cysts. We considered this to be an important subgroup analysis
with high biological plausibility, which developed from the included studies as they were considered for this review update.
Di@erences between 2010 review and this review update
The review author team revised the protocol, which was approved by the Cochrane Infectious Diseases Group editorial team on 14
September 2018 (see Appendix 2).
The main diIerences between this review and its previous version, Abba 2010, was the focus on the core question of whether anthelmintics
are of benefit or harm in the management of neurocysticercosis compared to no anthelmintic, as there is insuIicient evidence in previous
review versions to answer this question. Consequently, fewer comparisons were considered in this review update compared to previous
versions (e.g. comparison of diIerent anthelmintic treatment durations), with simplified intervention and control populations. Eight
studies included in the previous version of this review were therefore not eligible for inclusion (no supportive treatment comparator) in
the current review. The reasons for exclusion of these studies are provided in Characteristics of excluded studies. The same subgroup
stratifications were considered in this review compared to previous versions, but were not presented for every outcome, unless they
changed the message of the overall outcome. We believe this allowed for a more concise review with clearer implications.
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Medical Subject Headings (MeSH)
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MeSH check words
Adult; Child; Humans
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